Title:

Mechanistic within-host models of the asexual *Plasmodium falciparum* infection: a review and analytical assessment

Authors:

Flavia Camponovo^{1,2,3}, Tamsin E. Lee^{1,2}, Jonathan Russell⁴, Lydia Burgert^{1,2}, Jaline Gerardin⁵, Melissa A. Penny^{1,2*}

¹ Swiss Tropical and Public Health Institute, Basel, Switzerland

² University of Basel, Basel, Switzerland

³ current address: Center for Communicable Disease Dynamics, Department of Epidemiology, Harvard T. H. Chan School of Public Health, Boston, MA 02115, USA

⁴ Institute of Disease Modeling, Bill & Melinda Gates Foundation, 500 5th Ave N, Seattle, WA 98109, USA

⁵ Department of Preventive Medicine and Institute for Global Health, Northwestern University, Chicago IL, USA

* corresponding author

Keywords

Plasmodium falciparum, within-host mathematical models, asexual parasite dynamics

Abstract

Background: Malaria blood-stage infection length and intensity are important drivers of disease and transmission; however, the underlying mechanisms of parasite growth and the host's immune response during infection remain largely unknown. Over the last 30 years, several mechanistic mathematical models of malaria parasite within-host dynamics have been published and used in malaria transmission models.

Methods: We identified mechanistic within-host models of parasite dynamics through a review of published literature. For a subset of these, we reproduced model code and compared descriptive statistics between the models using fitted data. Through simulation and model analysis, we compare and discuss key features of the models, including assumptions on growth, immune response components, variant switching mechanisms, and inter-individual variability.

Results: The assessed within-host malaria models generally replicate infection dynamics in malaria-naïve individuals. However, there are substantial differences between the model dynamics after disease onset, and models do not always reproduce late infection parasitemia data used for calibration of the within host infections. Models have attempted to capture the considerable variability in parasite dynamics between individuals by including stochastic parasite multiplication rates; variant switching dynamics leading to immune escape; variable effects of the host immune responses; or via probabilistic events. For models that capture realistic length of infections, model representations of innate immunity explain early peaks in infection density that cause clinical symptoms, and model representations of antibody immune responses control the length of infection. Models differed in their assumptions concerning variant switching dynamics, reflecting uncertainty in the underlying mechanisms of variant switching revealed by recent clinical data during early infection. Overall, given the scarce availability of the biological evidence there is limited support for complex models.

Conclusions: Our study suggests that much of the inter-individual variability observed in clinical malaria infections has traditionally been attributed in models to random variability, rather than mechanistic disease dynamics. Thus, we propose that newly developed models should assume simple immune dynamics that minimally capture mechanistic understandings and avoid over-parameterisation and large stochasticity which inaccurately represent unknown disease mechanisms.

51 Background

52 The complex life cycle of *Plasmodium falciparum* (*P. falciparum*) involves many parasite
53 stages within both the mosquito and human host. *P. falciparum* induces complex and non-
54 sterilizing immune responses with repeated possible exposure in both the human host and
55 mosquito. The human blood-stage infection plays a crucial role in both disease burden and
56 transmission. Indeed, the length and magnitude of asexual parasite infection both drive
57 clinical symptoms within a host and the transmission potential through the level of
58 gametocytes. Thus, understanding within-host dynamics of the asexual parasite stage is
59 essential for both the development of drugs or other tools that target asexual or gametocytes
60 stages, and to assess burden or transmission dynamics. Within a human host, the *P.*
61 *falciparum* malaria cycle begins with sporozoites transmitted by infectious mosquito bites
62 that travel from the skin to the liver (1). Following replication in the liver, merozoites are
63 released into the bloodstream (1,2). These merozoites subsequently infect red-blood cells
64 (RBCs) and *in vitro*, approximately 16 merozoites emerge from a single merozoite in a 48
65 hour asexual blood-stage cycle (3). The blood-stage infection can persist for over 300 days if
66 untreated (4). A small fraction of asexual parasites convert into gametocytes (2), responsible
67 for the transmission from human to mosquito.

68 The asexual malaria life cycle drives clinical disease in an individual, with many processes
69 eliciting or evading the immune response (1). After invasion of a RBC, merozoites are no
70 longer directly exposed to immune actors. However, with hundreds of parasite proteins
71 exported to the erythrocyte's cell surface, immune effectors can recognize an infected RBC
72 (iRBC) (1). Naturally acquired immune responses recognize erythrocyte surface antigens of
73 iRBCs or antigens of the free merozoites (1), as well as antigens from liver and sexual stages
74 (5,6). Exported parasite proteins on the cell's surface give the cell the capability to adhere to
75 the blood vessel's wall, and thus evade splenic clearance (1). Furthermore, expression of the
76 most characterized exported protein, the erythrocyte membrane protein 1 (PfEMP1), can be
77 switched by the parasites from a large library of variants (1). New protein conformations are
78 produced to avoid detection, requiring the host to mount new immune responses (1). *P.*
79 *falciparum* escapes the immune response by successively expressing one out of 50–60 different
80 PfEMP1 genes (7). The switching mechanisms remain uncertain, but switching between the
81 PfEMP1 variants needs to be quick enough to evade the immune system and avoid splenic

clearance, while slow enough to avoid variant exhaustion and maintain the chronic nature of the infection (7). In endemic areas where populations are continuously exposed to malaria, repeated infections lead to acquired immunity, preventing severe cases of malaria and death but without leading to sterilizing protection for infection (1).

Many mathematical and statistical models have been developed to understand population level dynamics of malaria transmission and impact of interventions (reviewed in (8,9)), or to understand within host dynamics. Although there is a long history of mathematical modeling of malaria parasite within-host dynamics over the years, the substantial biological unknown elements of both parasite and host dynamics and the highly variable nature of infection patterns, make it difficult to assess model accuracy. Furthermore, as there is limited within-host data available for infections from either immunologically naïve or non-naïve individuals, there is no “gold standard” data set or model to compare. In 1999 Molineaux and Dietz reviewed published intra-host models (10), indicating the first within-host model of malaria was likely developed in 1989 by Anderson et al. (11). Anderson and colleagues (11) described parasite dynamics via a set of differential equations representing uninfected RBCs, iRBCs, merozoites, and immune effectors (11). This model along with the others reviewed led Molineaux and Dietz to conclude that existing models lacked realism and did not make quantitative comparisons to real data. They further concluded that the reviewed models did not allow for inter-individual variability in the outputs, even though a large variation in infection dynamics exists between individuals (10). In part to address these concerns, a substantial number of mechanistic within-host models, either standalone or used in larger transmission models, have since been developed. Most of these models were initially parameterized to data from naïve patients, but not necessarily to the limited available data from previously exposed individuals.

Several sources of detailed observations of parasite dynamics and densities in naïve patients exist. In the past, malaria infection was induced to generate fever to treat other illnesses. In particular between 1917–1963 malaria was used as a therapy to treat patients with tertiary neurosyphilis before the use of penicillin (12). The most extensive malaria therapy data set was collated between 1940 and 1963 by Collins and Jeffery (12–15). The published database consists of 318 patients treated at Columbia, South Carolina and the Milledgeville, Georgia laboratories (12). This data, referred to here as the malariatherapy dataset, includes patients infected with three different strains of *P. falciparum* for neurosyphilis treatment. The data

captures daily parasite counts by microscopy of both gametocyte and asexual parasites, and daily fever charts are available for each patient. This data set is the only detailed representation of the entire *P. falciparum* infection in a naïve population. Other malaria therapy data sets exist, for example of *P. vivax* infection in naïve and non-naïve individuals (16) (not further discussed here).

Over the last decade, many individual-based models of malaria transmission dynamics have been developed (reviewed in (8)); several of these include models of within-host asexual parasite dynamics (17–20). A recently published paper (21) investigated common biological assumptions made by within-host models, and concluded that current knowledge is insufficient to capture infection lengths and to explain the chronic nature of malaria infections. They further concluded their model was quite sensitive to small changes in the parameters leading to large instabilities in estimated infection lengths (21). Since asexual parasite dynamics are particularly important for modelling the effect of malaria interventions targeting humans (such as drugs or vaccines), the within-host model assumptions in these models have the potential to drive predictions at the population level, on either disease burden or intervention impact. Thus, with these within host models widely used in public health research, a good understanding of the overall dynamics, the assumptions, the uncertainties, and limitations of the models are key to critically assess and understand the predictions arising from the use of those models.

In this review, we analyzed within-host models of asexual parasitemia, and identified which components of the models drive predicted dynamics. We identified models used to investigate malaria interventions such as drugs or vaccines, either as stand-alone within-host models or used in combination with transmission models. The review and analytical assessment of each model, including the re-simulation of a subset of models to allow for deeper investigation, provides an overview of the main components of each model and their underlying assumptions. Rather than defining a gold standard, we discuss how models differ in their immune responses and parasite growth. Our comparison provides an understanding of the benefits and limitations in using these models, which directs and informs future work on within-host models of blood-stage parasitemia.

144 Methods

145 Models and simulation code:

146 We identified several mechanistic within-host models currently implemented in individual-
 147 based models (IBMs) from a recently published systematic review of IBMs (8), or used as
 148 stand-alone models to understand within host dynamics or assess malaria interventions (drugs
 149 or vaccines) targeting humans. The within-host models identified as being part of malaria
 150 IBMs are Molineaux *et al.* (22), Johnston *et al.* (23), Gatton and Cheng (24), Eckhoff (19),
 151 McKenzie and Bossert (25), and Gurarie *et al.* (26). We additionally included the models of
 152 Childs and Buckee (21) and Challenger (27) (see Fig. 1, and further details on the models in
 153 *Results* and in the Additional file 1). Five of the eight identified models were re-simulated for
 154 a deeper understanding of the underlying dynamics.

155 For the simulations, we used the open access code of Johnston *et al.* (23) to recreate the
 156 Johnston *et al.* model in Matlab (28). As both Johnston *et al.* (23) and later model Challenger
 157 *et al.* (27) were based on the model of Molineaux *et al.* (22), the code of Johnston *et al.* was
 158 used as base code to reproduce the Molineaux *et al.* (22) and the Challenger *et al.* (27)
 159 models. Challenger *et al.* provides open access code for their model in C++ (29) which we
 160 used to validate our model code. The model of Gatton and Cheng. (24) was not open access
 161 but we reproduced the model in Matlab. The model code for Eckhoff (19) was available from
 162 the author's affiliated groups (30).

163 Model simulation and assessment:

164 Each model was simulated 1750 times, which for the patient-specific model of Molineaux *et*
 165 *al.* corresponds to 50 simulations of the 35 malaria therapy patients used for
 166 parameterization. For all other models, this corresponds to 1750 independent realizations of
 167 the stochastic models.

168 Parameter values were fixed to the values defined in their respective publication (note that
 169 the parameters are either assumed from literature or fitted in their models, Additional file 1
 170 Table S3). The same stochastic multiplication rate of each PfEMP1 variants was used in the
 171 models of Molineaux *et al.* and Johnston *et al.*, except that for Johnston *et al.* any
 172 multiplication rate over 35 was resampled to be within the ranges defined by their model, as

defined in their publication. Other models either had a different definition of the parasite's multiplication rates (Challenger *et al.*) or a constant multiplication rate (Gatton and Cheng, and Eckhoff). Except for Eckhoff, our model simulations were undertaken in Matlab (28). The Eckhoff model was simulated in C++ (30). All subsequent analysis of results was performed in R (31). For the purpose of comparison, the models are all simulated for 600 days. Furthermore, we did not select for the best fit of the model to each patient and did not add measurement errors (as done by Molineaux *et al.*), as the aim was not to replicate the data but to illustrate the internal behavior of the models.

We initially assessed models via nine summary statistics for the malariatherapy data set. These summary statistics were first described in Molineaux *et al.* (22), and were later used as evaluation measures for several of the other models (23,24,27). Briefly, the nine summary statistics computed are *i)* the slope of the linear regression line from the first positive observed parasitemia to the first local maximum; *ii)* the $\log_{10}$ parasite density of the first local maximum, with a local maximum defined as a parasite density greater than the three preceding time steps ($t-1$ to $t-3$) and not lower than the three following time steps ($t+1$ to $t+3$); *iii)* the number of local maxima; *iv)* the slope of the linear regression through all the $\log_{10}$ local maxima; *v-vi)* the geometric mean and standard deviation of the geometric means between the local maxima; *vii-viii)* the proportion of positive observation in the first half and second half of the interval between the first and last positive observation; and *ix)* the last positive day (22). A positive parasite density observation was defined as an asexual parasite density equal to, or higher than, 10 iRBC per microliter. In the Gatton and Cheng model the number of iRBCs is modeled, and thus for consistency and for comparison to other models, the output was converted to iRBC per microliter assuming a body contains five liters of blood (24).

Assessment of parasite growth and host immunity for the re-simulated models

In addition to the summary statistics, we compared estimated overall parasite multiplication rates, the innate, variant specific, general adaptive, and total immune responses, and the subsequent variation across the simulations that reflects individual variation and stochasticity. We compared models by visual inspection of time series plots of these response components and established the model's main drivers of parasite density and infection length predictions.

To assess the modeled parasite growth, for the models which use a stochastic and variant-specific multiplication rate, we defined an average inherent parasite multiplication rate (across variants) at each time-step for each model. In Molineaux *et al.* and Johnston *et al.* each variant-specific parasite has its own multiplication rate drawn from a Normal distribution (22,23). Therefore, the average multiplication rate of all parasites at each time step is the weighted average of the variant-specific parasite multiplication rates, as follows:

$$\bar{M}(t) = \frac{\sum_{i=1}^{i=50} m_i p_i(t)}{P_{tot}(t)}, \quad eq. 1$$

where m_i is the multiplication rate of variant i , $p_i(t)$ the parasite density of variant i at time t , and $P_{tot}(t)$ the total parasite density at time t . For all other models, the overall parasite multiplication is an input parameter and thus does not need to be calculated.

To investigate the modeled immune responses, we categorized immune responses into innate (S_c), variant-specific (S_v), and general adaptive (S_m). Between Molineaux *et al.*, Johnston *et al.*, and Challenger *et al.*, those three terms are directly comparable across models, but for Gatton and Cheng and Eckhoff the terms are slightly different (see Additional file 1 Table S2). Where the variant specific immune response is tracked for each variant (in Molineaux *et al.*, Johnston *et al.* and Gatton and Cheng), the overall effect of the variant-specific immune response is the weighted average of the variant-specific immune response, as follows:

$$\bar{S}_v(t) = \frac{\sum_{i=1}^{i=50} S_{v,i}(t) p_i(t)}{P_{tot}(t)}, \quad eq. 2$$

where $S_{v,i}(t)$ is the effect of the immune response on variant i at time t , $p_i(t)$ the parasite density of variant i at time t , and $P_{tot}(t)$ the total parasite density at time t . The innate and general adaptive immune responses are described as an effect on the total parasite density and are reported as such without further modifications. All equations and comparison between the models are summarized in Additional file 1 Table S2.

227 Results

228 Overall model structure:

229 Via the systematic review of IBMs (8), six mechanistic within-host models were identified as
 230 part of the transmission models, as represented in Fig. 1, namely Molineaux *et al.* (22),
 231 Gatton and Cheng (24), Johnston *et al.* (23), Eckhoff (19), McKenzie and Bossert (25), and
 232 Gurarie *et al.* (26). An additional two models were identified through further literature
 233 search, namely Challenger *et al.* (27), and Childs and Buckee (21). The new quantitative
 234 results in the current study focus on five models, namely those of Molineaux *et al.* (22),
 235 Gatton and Cheng (24), Johnston *et al.* (23), Challenger *et al.* (27), and Eckhoff (19) (Fig. 1).
 236 The models of McKenzie and Bossert (25), Gurarie *et al.* (26), and Childs and Buckee (21)
 237 were included in the summary categorizations for comparison.

238 Most models reviewed here can generally be described in a simple discrete form

$$239 \quad Y_t = m_t Y_{t-1} R_t .$$

240 Here parasite densities or number of parasites Y_t , at time t , depend on the parasite's
 241 multiplication rate m_t reduced by the effect of immune response R_t . The immune response R
 242 can represent up to four components: the innate immune response, and the antibody-driven
 243 immune response defined by variant specific, cross-reactive, and adaptive immune responses,
 244 each component including different levels of stochasticity and different functions. The
 245 models can be relatively simple and reproduce a smoothed time-course of an infection, such
 246 as in McKenzie and Bossert, or include a higher level of complexity to describe more
 247 granular parasite dynamics including the typical peaks and troughs observed in clinical data.
 248 The latter usually involves explicit or implicit inclusion of a range of variant-specific
 249 parasites.

250 We reviewed each model via their detailed descriptions and equations in their respective
 251 publications. The models are fully described in the Additional file 1 and their main
 252 characteristics are described in Table 1, with more details of their immune response dynamics
 253 summarized in Table 2. We classified the type of equations used, the level of stochasticity
 254 integrated into the models, and detailed which dataset/s were used for calibration. We further
 255 categorized key features of parasite growth and immune dynamics for each model and

summarized in tables (Table 1 and Table 2). Equations were classified and divided into four descriptions 1) parasite growth defined by the merozoite multiplication factor; 2a) triggering of, and effect of, the innate immune response; 2b) PfEMP1 variant-specific immunity dynamics; and 2c) the general or non-PfEMP1 immune response dynamic. Fig. 2 illustrates the simplified dynamics and feedback between the host and parasite for the different models. The description of the parasite growth in each model is described in Table 1 (row “Assumed multiplication rate”) and the immune responses are described in Table 2. The complete description of each model is given in Additional file 1, and a brief summary is provided here.

Model specificities:

Molineaux *et al.* describe a mechanistic malaria parasite growth model including three components of the immune response, namely an innate immune response acting early in the infection; a variant-specific immune response for each variant-specific parasite population; and a general adaptive immune response acting on total parasite population. This model was intended to reproduce parasite densities from patients in the malariatherapy dataset (12), and describes each of the 50 variant-specific parasite populations within an infection. The model of Molineaux *et al.* was adapted by Johnston *et al.* by replacing two patient-specific parameters which trigger innate and general adaptive immune response with values drawn from a distribution (see Additional file 1). Challenger *et al.* further simplified the model by tracking total parasite density instead of 50 variant-specific parasite densities to reduce memory and computational requirements. The Johnston *et al.* and Challenger *et al.* models are referred to as *Molineaux adapted* models in this manuscript.

At a similar time to the publication of Molineaux *et al.*, Paget-McNicol *et al.* (32) published a stochastic model also including three immune response components and exploring different assumptions on switching dynamics of the PfEMP1 variant expression. This model was later adapted by Gatton and Cheng (24). Instead of a set of discrete model equations with stochastic parameters describing the asexual parasite density in the blood as in Molineaux *et al.*, the Gatton and Cheng model is stochastic and represent the total number of asexual parasites as a decision tree, where parasite numbers trigger choice of path in this decision tree and corresponding model equations (24). This model differs significantly from Molineaux *et al.* in regard to assumptions around the variant switching dynamics. Additionally, Gatton and Cheng include cross-reactivity between variant-specific immune responses, which was not

present in the model of Molineaux *et al*, although the general adaptive immune response might capture the effect of cross-reactivity implicitly.

More recently, two additional models by Eckhoff (19) and by Childs and Buckee (21) were developed. Eckhoff's model represents both continuous events such as immune responses to iRBC and discrete events such as the bursting of schizont and the associated immune responses. It also includes the concept of immune memory, capturing faster immune responses when an individual is re-exposed to a previously seen parasite variant. Additionally, it includes cross-reactivity between variant-specific antibody responses. In the early infection days, the probability of switching to a new variant increases with growing parasite population. The model developed by Childs and Buckee (21) is deterministic and in their work they explored a wide parameter space to assess variations in the infection dynamics with parameter choice. This model includes four different immune responses, namely innate; variant-specific; general adaptive immune responses; and similarly to the models of Eckhoff and Gatton and Cheng, includes cross-reactive immune response across parasite variants. Childs and Buckee investigate different variant switching dynamics, and explicitly limit parasite growth by available RBCs and competition of immune cells for each variant-specific immune response.

Despite these models incorporating detailed variant switching, the malariatherapy calibration datasets contain no information on gene expression profiles. Thus, there is no data describing variant expression and variant switching dynamics in the included patients. Instead, the models utilized understandings from the literature at the time of model development on potential structured switching; some of the models emphasize and discuss the uncertainty around the switching assumptions. Molineaux *et al*. and Johnston *et al* assume that immune pressure drives the switch to the expression of a new variant, based on biological studies with *P. knowlesi* infections in monkeys (7). In contrast, Paget-McNicol *et al*. refute the theory that switching depends on immunity because it can also be observed *in vitro* (33), and Gatton and Cheng's modified model also assumes no link between variant switching mechanisms and host immune pressure. To avoid all variants being expressed with equal chances, the models either assume different switching probabilities for each variant according to a geometric distribution (as in Molineaux *et al*, and in Johnston *et al*), limit the number of available variants to switch to in each cycle (as in Eckhoff), or assume two groups of variants, with either fast or slow switching behavior hypothesized at the time in (34) (as in Gatton and Cheng). The

model in Childs and Buckee explores different switching networks where all variants can switch to all other variants but with different probabilities and favoring some variants over others (which was adapted from (35)).

The two last models in this review, Gurarie *et al.* and McKenzie and Bossert, are simpler models which do not include variant switching and variant-specific immune responses: thus, including only two immune response components. Gurarie *et al.* propose a discrete model that assumes the effect of the adaptive immune response is forced to have “random falls” which implicitly allow for the immune response to lose effectivity when the parasite switches to a new variant. These falls in immune response decrease in magnitude during the course of an infection, as it is assumed that the general adaptive immune response builds up. The model of McKenzie and Bossert is the only model presented here which is built around a set of differential equations in a continuous time frame. Although capable of representing the general infection pattern (high initial peak followed by a decrease in parasitemia), the model is less granular, causing model predictions to resemble a smoothed version of the malariatherapy time-series data. This model was developed to allow for different genotypes to infect the host, and to explore the effect of different gametocyte dynamics on malaria transmission. This model does not include variants nor allow for variant switching dynamics to impact immune dynamics.

Including inter-individual variability:

The models attempt to replicate time-series observed in subsets of the malariatherapy data, either with formal or less formal fitting, or at least attempting to reproduce the general pattern observed. The Molineaux *et al.* model was fitted to 35 (out of 334) patients from the malariatherapy data, who were spontaneously cured and received no other treatment. Other models used a larger number of malariatherapy patients (Table 1) to be less restrictive and avoid selection biases. More details on model fitting can be found in Additional file 1 Table S3. There is considerable variation in infection dynamics across the malariatherapy patients, both in magnitude and structure of peaks of parasite numbers, and in length of infections (Fig. 3-4). This inter-individual variability inherently includes detection and clinical measurement error but is also a result of the stochastic nature of the biological mechanisms involved. These dynamics and observed variability are challenging to replicate. In order to capture the variability, models often implement stochasticity either in the parameters defining parasite multiplication rate and/or in the implementation and effect of the innate and general

adaptive immune responses (Molineaux *et al* and Molineaux *adapted*); by creating a stochastic model with most variables defined by Binomial or Normal distributions (Gatton and Cheng, and Eckhoff); or by fitting parameters separately to each patient (Molineaux *et al*, Mckenzie and Bossert, and Gurarie *et al*). Similarly, the model developed by Childs and Buckee is deterministic but can include different infection patterns by varying parameter values within the ranges specified in the publication (21).

Time series of parasite density

Time series of parasite density, summary statistics (described in *methods*) of true parasitemia profiles from 35 malariatherapy patients (12), alongside time series and summary statistics calculated from 1750 simulated parasitemia profiles for the five models, are shown in Fig. 3 and 4, and in Additional file 1 Table S1. We further note that although care was taken with new or adapted code, there may be small differences from the original publications.

The observed log₁₀ parasite densities of the 35 patients from the malariatherapy data varies significantly across the patients, a variability which appears to be accounted for in the models (Fig. 3). In Molineaux *et al*. most infections cease before day 200, with a subset of simulated parasitemia appearing to be chronic infections that do not end before the end of the simulation. The model of Johnston *et al*. increased the variant-specific immune response decay compared to Molineaux *et al*., thereby decreasing the immune response's efficiency. This results in increased simulated infection lengths compared to the simulations in Molineaux *et al*. The general shape of decay in parasite densities from Johnston *et al*. also appears to be more exponential-like compared to the other models, which is most likely a result of the more significant effect of the general adaptive immune response. In Challenger *et al*., simulations indicate a general pattern of two peaks, the first is followed by a decrease as a result of the innate immune responses, followed by a second wave of parasitemia that is controlled by the variant-specific and general immune responses. Simulations from Gatton and Cheng indicate a slightly different time course of peaks compared to those predicted from Molineaux *et al*. and the models adapted from Molineaux *et al*. Simulations from Gatton and Cheng indicate a general first peak with a sharp decrease in parasite densities with initial innate immune responses, followed by new peaks in parasite densities given the probabilistic approach taken in Gatton and Cheng (see Additional file 1 Table S2 for the equations). The general decline in predicted parasite densities (decreasing peaks) is not reflected in the summary statistics (Fig. 4). In Eckhoff's model the first peak is followed by

much lower peaks, resulting in a steeper slope of peaks in the summary statistics (Fig. 4). The average infection lengths are consistent with the 35 malariatherapy dataset, although it is worth noting that the Eckhoff model was fitted to a larger dataset from the malariatherapy patients including more than the 35 patients in Molineaux *et al.*

Total parasite multiplication rate during infection

We tracked each variant-specific parasite density in our simulations in all models except Challenger *et al.* and Eckhoff, the former because the equations do not explicitly model each variant and the latter due to the computational complexities of tracking each variant. The average multiplication rate at each time step is shown in Fig. 5. For Gatton and Cheng and for Eckhoff, the multiplication rate of the parasites, defined as the multiplication rate without the effect of any host immune response, is fixed at 16 per cycle and remains the same for all simulations and time (Fig.4d-e). For Johnston *et al.* and Molineaux *et al.*, each variant-specific parasite has its own multiplication rate drawn from a Normal distribution with mean of 16. For each time step, the overall multiplication rate for Johnston *et al.* and Molineaux *et al.* is thus the weighted average of the variant-specific multiplication (see *methods*). Therefore, these two models have a constant multiplication rate, in time, for each variant-specific parasite. However, the overall multiplication rate fluctuates over time, representing the competition between variant-specific parasites (with different multiplication factors), with new variants appearing, and other variants disappearing throughout the infection. For some simulations (Molineaux *et al.* and Johnston *et al.*), the overall multiplication rate is high at the beginning of the infection (Fig. 5a-b) and causes a peak in parasitemia density. The predicted infection length for a subset of simulations from both Molineaux *et al.* and Johnston *et al.* is very long, and in these subsets of simulations, the overall multiplication rate is in fact high throughout the infection (see Additional file Fig. S2).

In Challenger *et al.*, the multiplication rate at each time step is an input parameter of the model. It is both drawn from a Normal distribution with mean 16 and correlates with the previous time step (27) (see Additional file 1 Table S2). Thus, the median multiplication rate across all simulations remains constant at 16 by design (Fig. 5c). Taking the example of a single simulation (Fig. 6), the pattern of overall parasitemia in the Challenger model is less driven by the average growth rate in time compared with the simulations for Molineaux *et al.* and Johnston *et al.* (Fig. 6a-c). Molineaux *et al.* reported that a varying overall parasite multiplication rate, and thus the parasite inherent proliferation rate (without immunity), is

essential to recreate observed peaks in parasitemia in the dataset. Furthermore, we note that long lasting infections can only occur in models that express highly multiplying variants. Overall, this indicates infection dynamics in Molineaux *et al.* and Johnston *et al.* are primarily driven by stochasticity in the inherent growth of the parasites, whereas in Challenger *et al.*, Gatton and Cheng, and Eckhoff, the stochasticity in their predicted dynamics is driven more by immune responses and subsequent killing effects.

Immune response dynamics in the models

In terms of immune response variability between the simulations (and thus assumed to exist between individuals), the highest variance across individuals arises from the variant-specific immune response, followed by the innate immune response, with the general adaptive response being reasonably consistent across individuals for the models (Fig. 5-6). The key assumptions around immune dynamics for each model are summarized in Table 2. The simulated immune responses are shown for four models in the first plots in Fig. 5, and examples of single simulations are shown in Fig.5. Note that in Gatton and Cheng and in Eckhoff, the effects of the immune responses are drawn from Binomial distributions; thus, the variability in the effects of the immune responses are not entirely captured in the immune time plots of Fig. 3 and Fig. 5.

The innate immune response is mainly active at the beginning of the infection (approximately the first 20-50 days in the different models) as it responds directly to high levels of parasite density. In Eckhoff's model, the innate immune response is modulated by the adaptive immune response, reducing with increasing antibodies against the parasite population, making this model the only one with direct feedback between innate and adaptive immune response.

The variant specific immune response, effective against variant-specific parasite after delay, is modeled for each variant explicitly in Molineaux *et al.*, Johnston *et al.*, Gatton and Cheng, and Eckhoff. The increased decay rate in Johnston *et al.* compared to Molineaux *et al.* leads to a reduction in the immune responses (Fig. 5). In Challenger *et al.*, once the variant-specific immune response is activated, it is quickly efficient in reducing parasite densities compared to the other two models (steeper slope in the variant-specific immune response curve in Fig. 5). This efficient immune response likely explains the steep decrease after the first wave of parasite density. In Gatton and Cheng, the variant-specific response is activated when the

variant-specific parasite density reaches the threshold of 12 PRBC/ μ l (24), and the magnitude is increased if the antibody was already produced during the infection. When there are high peaks throughout the infection, the variant-specific immune response remains very active throughout the predicted infections from Gatton and Cheng.

The general adaptive immune response increases in time since the start of the infection, responding to the cumulative parasite density (Molineaux *et al.*, Molineaux adapted, Eckhoff, McKenzie and Bossert, and Gurarie *et al.* model), time (Gatton and Cheng) or a combination of both time and parasite density (Childs and Buckee). An important finding is that by comparing all three immune responses and the total net immune response (Fig. 5 and 6), the general immune response is the main effector of reducing parasite density in all models approximately after 50 days from start of infection. However, the variant immune response will ultimately end the infection. The decrease of the critical density for the general adaptive immune response in Johnston *et al.* and Challenger *et al.* compared to Molineaux *et al.* (see model description and Table S2 in Additional file 1) leads to a higher effect of the general adaptive immune response in those models, which compensates for the weaker effect of the variant-specific immune response.

Discussion

In this study, we have reviewed eight published mechanistic within-host models of the asexual blood-stage dynamics of *P. falciparum*, of which we reproduced five. We compared predicted time-series of asexual parasitemia, modelled growth rates, innate immune responses, variant-specific immune responses, and general adaptive immune responses. The models varied widely in complexity. Whilst rather simple models such as McKenzie and Bossert have the advantage that they do not rely heavily on assumptions of unknown biological mechanisms, they reproduce less detailed patterns of infection. In contrast, more complex models such as Eckhoff or Childs and Buckee capture more detailed immune mechanisms but also include more uncertainty. Understanding the variation in multiplication rates, versus immune responses, or random effects and measurement error, and their impact on parasite density variations is particularly important when the models are included in broader investigations of the effect of a vaccine, drug or other

interventions aimed to modify parasite growth patterns. The overview presented here provides a general understanding of those models.

Model composition varies in complexity and uncertainty

Parasite and host dynamics are represented in the mechanistic models via detailed description of the parasite replication dynamics, and up to four host immune responses. Each model has its own additional complexity, specifications, and advantages. For example, to obtain increased detail of the host's response, some models include red blood cell availability and limit the maximum immune response capacity. Or, to include more details in the parasite dynamics, some models include specific variant switching mechanisms. Models generally define a negative feedback loop between the parasite density or cumulative parasite density since the start of the infection and the effect of the immune responses, and in addition some models add the time of infection (Gatton and Cheng, Childs and Buckee, Eckhoff) as a determinant for the magnitude of the general immune response.

Including stochasticity in the models is particularly relevant for the within host dynamics of *P. falciparum* as the infection patterns observed in the malaria therapy data are highly variable among patients. Our analysis highlighted that the Molineaux *et al.* and the *Molineaux adapted* models have likely allocated too much stochasticity to the individual parasite multiplication rates, thus masking other mechanisms and placing relatively less importance on immune responses. Furthermore, for these models, we found their assumptions concerning the inherent multiplication rates of the parasites differ from other models, along with assumptions of large variability in the variant-specific parasite multiplication rates in the absence of any immune response. These dynamics were found to be essential in the Molineaux *et al.* and *Molineaux adapted* models to reproduce clinical malaria therapy patterns of infection, rather than immune responses (22). In particular, in Molineaux *et al.* and Johnston *et al.*, longer infections result from the expression of variants with a high multiplication rate towards the end of the infections for later variants. In contrast, the other models did not rely on variation to capture infection patterns. Instead, variation was mainly included in the control of infection due to immune responses and switching mechanisms.

For models including multiple parasite variants, the variant switching dynamics are an important mechanism driving the parasitemia predictions. The switching dynamics define how the parasite goes from expressing one PfEMP1 variant to another one at the next

generation in order to evade the immune response. Switching dynamics in the models have been assumed to respond to the variant specific immune response (Molineaux *et al.* and Johnston *et al.*), to the current variant population size (Eckhoff), or were determined by more sophisticated switching networks (Childs and Buckee, Gatton and Cheng). In the re-simulated models, the variant-specific immune response, which is driven by the parasite's variant switching dynamics either explicitly, or implicitly in Challenger *et al.*, was the most variable component of the immune responses across individuals. This is in contrast to the data available to inform switching dynamics over the course of an infection, which is limited to early days of infection (36–38).

The various assumptions around the mechanisms of action of the different immune responses and the interplay between parasite and host highlight the challenge of realistically reproducing the time-series observed in the malariatherapy dataset, especially the inter-individual variability. This challenge is confounded since there is limited knowledge of the biological mechanisms at play.

Parasite multiplication rates might be lower than initially assumed

It is commonly agreed that a single iRBC produces 16 merozoites (3), of which a portion successfully invade new erythrocytes. Growth rates *in vivo* are more difficult to measure, and compared to the assumed multiplication factor of 16, includes the host-parasite interactions which reduce the observed parasite growth. Several independent statistical models previously estimated parasite growth at onset of infections in both malaria therapy or volunteer infection studies (VIS). Estimates from the malariatherapy dataset range between 10-18 (39), or 6-24 (20). In malaria VIS the growth factor was estimated to be between 12-15 (40), and in the control cohort of vaccines AMA1-based vaccine challenge between 14-21 (41). More recently, estimated *ex-vivo* multiplication factors for different malaria genotypes were found to be between 2-11 for laboratory strains and new clinical isolates (42). One hypothesis explaining the variation among parasite growth relies on the differential capacity of the PfEMP1-variants to evade splenic clearance, with the hypothesis that a subgroup of PfEMP1 expressing parasites might be fast growing (due to increased cytoadherence and thus decreased splenic clearance) (43). This mechanism may explain differing growth rates among parasites expressing different variants, and explain apparent higher multiplication rates in naïve individuals if their parasites express the fast growing PfEMP1 subgroup (43). Variance in parasite multiplication rates among clones and among infections across individuals is possible due to this variance in

successful avoidance of splenic clearance during blood-stage replication, however, it is unclear whether the range should include an overall multiplication factor as large as 32 or 35, as in some models reviewed here (namely in (21–23,27)).

Variant switching and immune response modeling are limited by current knowledge

Switching mechanisms are not well understood, and it remains unclear if the switching mechanisms are driven by antibody response (as in [1], [2]) or are not directly influenced by the immune pressure (as in (21,24)). In contrast to the assumptions made in the models reviewed here, it is likely that parasites express more than one variant, if not all variants, during the first blood stage generation. As highlighted by Childs and Buckee (21), this finding challenges the current understanding on the underlying mechanisms leading to chronic infections. The concept of cross-reactivity, suggested as a mechanism necessary for chronic infections (44) and included explicitly in Gatton and Cheng, Childs and Buckee, and in Eckhoff would not be applicable, as modeled and explored by Childs and Buckee, if the majority of the variants are expressed at the onset of asexual parasitemia (45). The lack of understanding about the switching dynamics supports the assumptions in Challenger *et al.*, as they only model total parasitemia without modeling switching between variants. The models described by McKenzie and Bossert, and Gurarie *et al.*, are less complex and do not model variant-specific parasitemia, offering potential modeling alternatives when detailed mechanisms of immune response are not needed. To our knowledge, there are few biological studies on the kinetics and interplay of the immune responses as defined by the models (innate, variant specific, and/or adaptive immune response). As such it is unclear how much each immune component affects the overall time course of infection. Therefore, it is not surprising that models differ in the relative importance of general or variant-specific immune responses. Moreover, in the absence of a clear biological understanding of the variability in infection time-series, model stochasticity remains an important driver of the modelled immune and parasite dynamics.

Further data for new models

It is essential to highlight here that the malariatherapy dataset cannot be considered as a typical time course of an infection, as the data come from patients with severe neurosyphilis, who were malaria naïve, and did not include children. Furthermore, inoculations were limited to a restricted set of parasite strains. Thus, although the malariatherapy data are the only detailed data available on infection time-course, models are not strictly evaluated by their

ability to reproduce malariatherapy-like infections. Data on early infections are available in high detail from VIS. They provide precise quantification of parasitemia at much lower detection threshold than the malariatherapy data, and variant expression dynamics or other genetic traits relevant for understanding the dynamics in the first few days of blood stage infection can now be informed by such studies. Beyond early infections, models need to rely on longitudinal field data to assess their performance. Longitudinal field data are extremely important to explore the dynamics in realistic settings, with individuals living in endemic areas who are repeatedly exposed to malaria, including children who are most at risk for the disease, and including a range of genetic diversity and complexity of infection. Because immunity builds up with age and exposure (46), and genetic diversity is a result of immune pressure, longitudinal and cross sectional field studies which include genetic analysis give important insights in malaria infection dynamics.

The current analysis and review focused on infections in naïve individuals and we did not review the models for their ability to capture infections in pre-exposed individuals. Although data is lacking, the immune effect of pre-exposure could be added to the models as a second step, for example by adding an overall reduction factor that would lower the magnitude of the parasite density in function of age and/or exposure, similar to an empirical model by Maire *et al.* (47). The effect of co-infection was not included here and its implementation was a focus of the Childs and Buckee model (21), which hypothesizes that co-infections and super-infections have different effects based on the timing of the second infection, and that the effects of multiple infections seem to be poorly understood, and thus poorly included in models (21). Recently many field studies focusing of genetic data and analysis are giving insights in the effect and dynamics of multiple infections on a population scale (for example (48,49)), yet empirical data on the time course of complex infections are sparse and insufficient to validate models of co-infections, relying on data from mouse models for detailed infection dynamics (50,51).

Conclusions

This review provides insights on existing models of asexual *P. falciparum* blood-stage infections, and some insights on both known and unknown biological mechanisms driving infection dynamics. Blood-stage parasite densities are at the core of malaria transmission,

599 morbidity and mortality. Thus, population models that include models of within-host parasite
600 dynamics to estimate the impact of blood-stage drugs or vaccine, or estimate the impact of
601 parasite resistance, should be aware of the underlying assumptions made in the within-host
602 model and how those changes effect infection dynamics. As in any modeling exercise, the
603 choice of the model and its degree of complexity should depend on the specific biological,
604 epidemiological, or public health question, and should account for available data.

605 List of abbreviations

- 606 (i)RBC: (infected) red blood cell
 607 *P. falciparum* : *Plasmodium falciparum*
 608 PfEMP1: Plasmodium falciparum erythrocyte membrane protein 1
 609 VIS : Volunteer infection studies

610 Declarations

- 611 Ethics approval and consent to participate
 612 Not applicable
 613
 614 Consent for publication
 615 Not applicable
 616
 617 Availability of data and materials
 618 The outputs generated and analyzed during the current study are available from the
 619 corresponding author on reasonable request
 620
 621 Competing interests
 622 The authors declare that they have no competing interests
 623

624 Funding

- 625 The design, analysis, and writing of the manuscript was funded by the Swiss National
 626 Science Foundation through the SNF Professorship of MAP: PP00P3_170702

627 Authors' contributions

- 628 Conception: FC, MAP - Design: FC, MAP - Analysis: FC, MAP, JR and JG - Interpretation:
 629 FC, MAP, TEL, LB, JR, JG - Drafted the work: FC - Substantial revision: FC, MAP, TEL,
 630 LB. All authors have reviewed and approved the manuscript

631 Acknowledgements

632 We acknowledge and thank our colleagues in the Infectious Disease Modeling unit of the
633 Swiss Tropical and Public Health Institute for fruitful discussions that led to improvement of
634 this work. We thank Lauren Childs for discussions on her model in particular as well as for
635 the other models.

Figure 1: Identified within-host models of asexual parasite blood stage infection. Models are ordered by their publication date on the vertical and horizontal axis, with models adapted from another model displayed on the same row and linked with arrows. Dashed squares represent models that have been used in IBMs according to the systematic review of [6], and colored squares highlight the models that are simulated in this study, where the colors correspond to the results plotted in Fig. 3-6. Text in each box indicates a brief description of the main features or differences of the models. A more detailed description of the models can be found in the supplementary material or in the source publications (17–19,21,22,24,27)

a) Molineaux *et al.*, and Johnston *et al.*

b) Challenger *et al.*

c) Gatton & Cheng

d) McKenzie & Bossert

e) Eckhoff

f) Gurarie *et al.*

g) Childs & Buckee

Figure 2: Schematic overview of the main within host dynamics. A simplified representation of the main immune and parasite dynamics for a) Molineaux *et al.* and Johnston *et al.*, b) Challenger *et al.*, c) Gatton *et al.*, d) Mckenzie and Bossert, e) Eckhoff, f) Gurarie *et al.*, and g) Childs and Buckee. Each model is represented by the main parasite components (left box), the host-immune component (right box) and additional factors influencing parasite dynamics (bottom circles). Models either describe overall infected red blood cells (iRBC) or total iRBC result from a sum of variant specific iRBC (var

656 *1,...,i).Asexual multiplication (m) and variant switching of the parasite are represented by*
657 *black arrows, and feedbacks between parasite and host components are represented by green*
658 *arrows or red bar-headed lines for positive or negative effects, respectively. The weaker*
659 *effect due to cross-reactive immune response is represented by dashed bar-headed lines. A*
660 *more detailed description of the models can be found in the supplementary material, or in the*
661 *source publications (17–19,21,22,24,27)*
662

663

664 **Figure 3: Observed and predicted total asexual parasite density.** From top to bottom, the
 665 observed $\log_{10}$ asexual parasite density in time of the 35 patients from the malaria therapy
 666 dataset (d), and the predicted $\log_{10}$ asexual parasite density in time from the Molineaux et al.
 667 (M), the Johnston et al. (J), the Challenger et al. (C), the Gatton & Cheng. (G), and the
 668 Eckhoff simulations (E). The solid line represents the median across the 1750 simulations per
 669 model or 35 patients for the dataset, the colored shaded area the interquartile range (Q25-
 670 Q75) and the light grey shaded area the minimum and maximum. The horizontal dashed line
 671 indicated the threshold of positive observation (10PRBC/ μ l)

Figure 4: Descriptive summary statistics of the observed and predicted time course of total asexual parasite density. The nine descriptive summary statistics as defined in Molineaux et al. (see methods), for the dataset and the 5 models (by color). Squares indicate the median, bars the interquartile range and the grey dots the minimum and maximum. In each plot, from left to right, the estimates are shown for the 35 patients from the malaria therapy dataset (d), and for the simulated models of Molineaux et al. (M), Johnston et al. (J), Challenger et al. (C), Gatton & Cheng. (G), and Eckhoff (E).

683 **Figure 5: Immune responses, multiplication rates and asexual parasite densities in**
 684 **different models.** Each panel shows, from top to bottom, 1. the effect of the innate immune
 685 response, 2. the effect of the variant specific immune response (see methods for calculations),
 686 3. the effect of the general adaptive immune response, 4. the net effect of the product of the
 687 three immune responses, 5. the average (across variants, see methods) multiplication rate, 6.
 688 the $\log_{10}$ asexual density and 7. the product of the overall multiplication rate with the net
 689 effect of the immune response. The x-axis represents days of infection, the solid line the
 690 median, the shaded area the interquartile range (Q25-Q75) and the grey lines the minimum
 691 and maximum resulting from the 1750 simulations. The horizontal dashed green line
 692 represents an overall multiplication rate of 16, the horizontal dashed black line indicates the
 693 threshold of positive density (10PBRC/ μ l). Results are shown for **a)** Molineaux *et al.*, **b)**
 694 Johnston *et al.*, and **c)** Challenger *et al.*, **d)** Gatton & Cheng, and **e)** Eckhoff.

a) Molineaux *et al*b) Johnston *et al*c) Challenger *et al.*

Figure 6: Example of the immune responses, multiplication rates and asexual parasite densities in single simulations from several models. Each panel shows, from top to bottom, 1-3. the effect of the innate, variant specific (see methods for calculations), and general adaptive immune responses; 4. the net effect of the product of the three immune responses; 5. the overall (across variants, see methods) multiplication rate; 6. the log₁₀ asexual density and variant specific asexual parasite density; and 7. the product of the overall multiplication rate with the net effect of the immune response. The x-axis represents days of infection. The horizontal dashed green line represents an overall multiplication rate of 16, the horizontal dashed black line indicates the threshold of positive density (10 PBRC/μl). Results are shown for a) Molineaux *et al.*, b) Johnston *et al.*, c) Challenger *et al.*, d) Gatton & Cheng, and e) Eckhoff.

708 **Table 1: Overview and main description of the models.** The model description includes the main characteristics of variant or total parasite
709 growth, the stochastic components, and the data used for fitting.

General model structure, and parasite dynamics								
Models	Molineaux <i>et al.</i>	Johnston <i>et al.</i>	Challenger <i>et al.</i>	Gatton & Cheng	Eckhoff	Childs & Buckee	Gurarie <i>et al.</i>	McKenzie & Bossert
Adapted models								
Publication year	2001	2013	2017	2004	2012	2015	2012	2005
Discrete (2 days time step) or continuous	Discrete			Discrete	Mixed	Discrete	Discrete	Continuous
Patient specific parameters	Yes*	No		No	No	No	Yes**	Yes***
Tracks all parasite variants	Yes	Yes	No	Yes	Yes	Yes	No	No
Number of variants at the start of infection	1		-	5	5	5	-	-
Main assumption on variant switching dynamics	Dependent on variant immune response. Different switching probability for each variant follows geometric distribution		-	Fast and slow switching variants. Independent of immune response, described in (52)	Switching rate per iRBC, thus larger population have higher probability to introduce new variant. Parasites can switch to 7 available variants, out of a total of 50 variants, in each round.	Different switching networks are investigated. Network assumed from (35)	Not explicit	-

Assumed multiplication rates	different for every variant but constant in time ($\sim \mathcal{N}(\mu_m = 16, \sigma_m = 10.4)$)		(for overall parasites) different for every time step, but correlated to previous time step	16 (const)	16 (const)	variant-dependent but constant in time ($\sim \mathcal{N}(\mu_m = 16, \sigma_m = 8)$)	range between 15-50, median 23.91	-
Additional assumptions on growth	-	-	-	-	dependent on RBC availability	dependent on RBC availability	dependent on RBC availability	-
Variability included in the model: • stochastic parameters	multiplication rate, patient specific parameters for the critical densities for innate and general adaptive immune response		critical densities for innate and general adaptive immune response, and growth rate			most parameters chosen stochastically (for sensitivity analysis)	merozoite invasion probability and replication rate, innate and adaptive immune response efficiency and activation threshold, antigenically distinct variant clusters	None
• probabilistic equations				effect of immune responses, antibody production, variant switching	variant switching, effect of variant specific and innate immune response		falls of immune response due to antigenic switch taken at random	None
Data used for the fitting^a	35 patients ¹			90 patients ²	Malariatherapy data ³	- ⁴	122 malaria therapy patients	63 malaria therapy patients ⁵

* Patient specific critical densities for innate and general adaptive immune response calculation.

** **Model calibrated to each of the infection chart separately to generate 50 best parameter sets for each calibrated malariatherapy data set.**

*** **Model fitted to each of the infection chart separately, thus all parameters take a patient specific value or are averaged across patients.**

¹ *P. falciparum* infections classified as spontaneous cures, out of a total of 334 patients in the malariatherapy data.

² Patients from the malariatherapy dataset not treated to modify the primary parasitaemia, and with no curative or subcurative treatment after the primary attack.

³ Number of patients is not specified. Includes those with high initial peaks and treated during the primary peak.

⁴ The model focuses on the effect on outcome of varying the parameters, within biologically reasonable ranges.

⁵ inoculated with McLendon. From the patients only the days before any drug or other interventions were used, which included a range between 22 – 159 days of infection.

^a as described in the initial publications, the models might have been re-fitted when updated, implemented in other research projects, or implemented in transmission models.

711 **Table 2: Overview and main immune dynamics of the models.** The model description includes the main characteristics of innate, variant
712 specific, and general adaptive immune response.

General model structure, and parasite dynamics								
Models	Molineaux <i>et al.</i>	Johnston <i>et al.</i>	Challenger <i>et al.</i>	Gatton & Cheng	Eckhoff	Childs & Buckee	Gurarie <i>et al.</i>	McKenzie and Bossert
Adapted models								
Assumptions on innate immune response	dependent on total parasite density at a given time				dependent on density of each parasites expressing variants for which there is no antibody response, and on the rupturing of iRBCs	dependent on total parasite density at a given time and is capped by a maximum efficacy term	dependent on iRBC density	dependent on cumulative asexual parasite density
Assumptions on variant specific immune response	dependent on the variant specific parasite density, and lasting in time with a decaying intensity	dependent on the total parasite within a time frame preceding the time of response, and on time after infection start	Triggered by a variant specific parasite density threshold, dependent on the time after infection start, and the magnitude increases if the antibody has been produced previously		dependent on the variant specific parasite density	dependent on the variant specific parasite density, a maximum growth and decay rate. And is restricted by total number of immune cells available	not explicit, but adaptive immune response includes random falls due to implicit variant switching	-
Assumptions on general adaptive immune response	depends on cumulative total parasite density			dependent on the time after the start of the infection	modeled as immune response against merozoite antigens - increase every 2 days, dependent on parasite density	dependent on cumulative number or days the total parasite population is above 10^7	dependent on iRBC density and combined innate and adaptive effector pool	Dependent on cumulative asexual parasite density, does not decay in time
Includes cross-reactivity	No	Not explicitly		Yes, the variant specific response approximately kills 5% of all other variants	Yes, response to variants randomly assigned to 5 subgroups	Yes, response to variants randomly assigned to subgroups	No	Yes, immune response to one genotype can be activated by the presence of another genotype
Other comments	innate and adaptive immune			parameters differ with different parasite strains	immune memory is included in the model	Detailed sensitivity analysis resulted in		

	response include patient specific parameters					significant impact on the model's outcome of small changes in parameter values, highlighting the challenged face by within host models		
--	--	--	--	--	--	---	--	--

713

714

- 716 1. Cowman AF, Healer J, Marapana D, Marsh K. Malaria: Biology and Disease. *Cell*. 2016
717 Oct;167(3):610–24.
- 718 2. Miller LH, Ackerman HC, Su X, Welles TE. Malaria biology and disease pathogenesis:
719 insights for new treatments. *Nat Med*. 2013 Feb;19(2):156–67.
- 720 3. Matthews H, Duffy CW, Merrick CJ. Checks and balances? DNA replication and the cell
721 cycle in *Plasmodium*. *Parasit Vectors*. 2018 Dec;11(1):216.
- 722 4. Felger I, Maire M, Bretscher MT, Falk N, Tiaden A, Sama W, et al. The Dynamics of
723 Natural *Plasmodium falciparum* Infections. Gosling RD, editor. *PLoS ONE*. 2012 Sep
724 18;7(9):e45542.
- 725 5. Idris ZM, Chan CW, Kongere J, Hall T, Logedi J, Gitaka J, et al. Naturally acquired
726 antibody response to *Plasmodium falciparum* describes heterogeneity in transmission on
727 islands in Lake Victoria. *Sci Rep*. 2017 Aug 22;7(1):9123.
- 728 6. Ouédraogo AL, Roeffen W, Luty AJF, de Vlas SJ, Nebie I, Ilboudo-Sanogo E, et al.
729 Naturally Acquired Immune Responses to *Plasmodium falciparum* Sexual Stage
730 Antigens Pfs48/45 and Pfs230 in an Area of Seasonal Transmission ▽. *Infect Immun*.
731 2011 Dec;79(12):4957–64.
- 732 7. Kyes SA, Kraemer SM, Smith JD. Antigenic Variation in *Plasmodium falciparum* : Gene
733 Organization and Regulation of the *var* Multigene Family. *Eukaryot Cell*. 2007
734 Sep;6(9):1511–20.
- 735 8. Smith NR, Trauer JM, Gambhir M, Richards JS, Maude RJ, Keith JM, et al. Agent-based
736 models of malaria transmission: a systematic review. *Malar J* [Internet]. 2018 Dec [cited
737 2019 Mar 31];17(1). Available from:
738 <https://malariajournal.biomedcentral.com/articles/10.1186/s12936-018-2442-y>
- 739 9. Mandal S, Sarkar RR, Sinha S. Mathematical models of malaria - a review. *Malar J*. 2011
740 Jul 21;10:202.
- 741 10. Molineaux L, Dietz K. Review of intro-host models of malaria. *Parassitologia*.
742 1999;41:221–31.
- 743 11. Anderson RM, May RM, Gupta S. Non-linear phenomena in host—parasite interactions.
744 *Parasitology*. 1989 Jan;99(S1):S59.
- 745 12. Collins WE, Jeffery GM. A Retrospective Examination of Sporozoite- and Trophozoite-
746 Induced Infections with *Plasmodium Falciparum*: Development of Parasitologic and
747 Clinical Immunity during Primary Infection. *Am J Trop Med Hyg*. 1999 Jul
748 1;61(1_Supplement):4–19.

- 749 13. Collins WE, Jeffery GM. A retrospective examination of mosquito infection on humans
750 infected with *Plasmodium falciparum*. *Am J Trop Med Hyg*. 2003 Mar 1;68(3):366–71.
- 751 14. Collins WE, Jeffery GM. A retrospective examination of sporozoite-induced and
752 trophozoite-induced infections with *Plasmodium ovale*: development of parasitologic
753 and clinical immunity during primary infection. *Am J Trop Med Hyg*. 2002 May
754 1;66(5):492–502.
- 755 15. Collins WE, Jeffery GM. A Retrospective Examination of the Patterns of Recrudescence
756 in Patients Infected with *Plasmodium Falciparum*. *Am J Trop Med Hyg*. 1999 Jul
757 1;61(1_Supplement):44–8.
- 758 16. Roberts JM, Jeffery GM, Collins WE. A retrospective examination of reinfection of
759 humans with *Plasmodium vivax*. *Am J Trop Med Hyg*. 2004 Jun 1;70(6):642–4.
- 760 17. Gurarie D, Karl S, Zimmerman PA, King CH, St. Pierre TG, Davis TME. Mathematical
761 Modeling of Malaria Infection with Innate and Adaptive Immunity in Individuals and
762 Agent-Based Communities. Paul RE, editor. *PLoS ONE*. 2012 Mar 28;7(3):e34040.
- 763 18. McKenzie FE, Bossert WH. An integrated model of *Plasmodium falciparum* dynamics. *J*
764 *Theor Biol*. 2005 Feb;232(3):411–26.
- 765 19. Eckhoff P. *P. falciparum* Infection Durations and Infectiousness Are Shaped by
766 Antigenic Variation and Innate and Adaptive Host Immunity in a Mathematical Model.
767 Snounou G, editor. *PLoS ONE*. 2012 Sep 19;7(9):e44950.
- 768 20. Dietz K, Molineaux L, Raddatz G. Mathematical model of the first wave of *Plasmodium*
769 *falciparum* asexual parasitemia in non-immune and vaccinated individuals. *Am J Trop*
770 *Med Hyg*. 2006 Aug 1;75(2_suppl):46–55.
- 771 21. Childs LM, Buckee CO. Dissecting the determinants of malaria chronicity: why within-
772 host models struggle to reproduce infection dynamics. *J R Soc Interface*. 2015 Feb
773 11;12(104):20141379–20141379.
- 774 22. Molineaux L, Diebner HH, Eichner M, Collins WE, Jeffery GM, Dietz K. *Plasmodium*
775 *falciparum* parasitaemia described by a new mathematical model. *Parasitology*
776 [Internet]. 2001 Apr [cited 2019 Mar 21];122(04). Available from:
777 http://www.journals.cambridge.org/abstract_S0031182001007533
- 778 23. Johnston GL, Smith DL, Fidock DA. Malaria's Missing Number: Calculating the Human
779 Component of R_0 by a Within-Host Mechanistic Model of *Plasmodium falciparum*
780 Infection and Transmission. Antia R, editor. *PLoS Comput Biol*. 2013 Apr
781 18;9(4):e1003025.
- 782 24. Gatton ML, Cheng Q. Investigating antigenic variation and other parasite host
783 interactions in *Plasmodium falciparum* infections in nave hosts. *Parasitology*. 2004
784 Apr;128(4):367–76.
- 785 25. McKenzie FE, Bossert WH. An integrated model of *Plasmodium falciparum* dynamics. *J*
786 *Theor Biol*. 2005 Feb;232(3):411–26.

- 787 26. Gurarie D, Karl S, Zimmerman PA, King CH, St. Pierre TG, Davis TME. Mathematical
788 Modeling of Malaria Infection with Innate and Adaptive Immunity in Individuals and
789 Agent-Based Communities. Paul RE, editor. PLoS ONE. 2012 Mar 28;7(3):e34040.
- 790 27. Challenger JD, Bruxvoort K, Ghani AC, Okell LC. Assessing the impact of imperfect
791 adherence to artemether-lumefantrine on malaria treatment outcomes using within-host
792 modelling. Nat Commun [Internet]. 2017 Dec [cited 2019 Mar 21];8(1). Available from:
793 <http://www.nature.com/articles/s41467-017-01352-3>
- 794 28. MATLAB and Statistics Toolbox Release 2018b, The MathWorks, Inc., Natick,
795 Massachusetts, United States.
- 796 29. Challenger J. JDChallenger/adherence_project [Internet]. 2017 [cited 2019 Apr 25].
797 Available from: https://github.com/JDChallenger/adherence_project
- 798 30. Bershteyn A, Gerardin J, Bridenbecker D, Lorton CW, Bloedow J, Baker RS, et al.
799 Implementation and applications of EMOD, an individual-based multi-disease modeling
800 platform. Pathog Dis [Internet]. 2018 Jul 1 [cited 2020 Dec 25];76(5). Available from:
801 <https://academic.oup.com/femspd/article/doi/10.1093/femspd/fty059/5050059>
- 802 31. R Development Core Team (2008). R: A language and environment for statistical
803 computing. R Foundation for Statistical Computing, Vienna, Austria. ISBN 3-900051-
804 07-0, URL <http://www.R-project.org>.
- 805 32. Paget-Mcnicol S, Gatton M, Hastings I, Saul A. The Plasmodium falciparum var gene
806 switching rate, switching mechanism and patterns of parasite recrudescence described
807 by mathematical modelling. Parasitology [Internet]. 2002 Mar [cited 2019 Mar
808 21];124(03). Available from:
809 http://www.journals.cambridge.org/abstract_S0031182001001160
- 810 33. Peters J, Fowler E, Gatton M, Chen N, Saul A, Cheng Q. High diversity and rapid
811 changeover of expressed var genes during the acute phase of Plasmodium falciparum
812 infections in human volunteers. Proc Natl Acad Sci. 2002 Aug 6;99(16):10689–94.
- 813 34. Bull PC, Berriman M, Kyes S, Quail MA, Hall N, Kortok MM, et al. Plasmodium
814 falciparum Variant Surface Antigen Expression Patterns during Malaria. PLoS Pathog.
815 2005;1(3):e26.
- 816 35. Noble R, Christodoulou Z, Kyes S, Pinches R, Newbold CI, Recker M. The antigenic
817 switching network of Plasmodium falciparum and its implications for the immuno-
818 epidemiology of malaria. Pascual M, editor. eLife. 2013 Sep 17;2:e01074.
- 819 36. Wang CW, Hermesen CC, Sauerwein RW, Arnot DE, Theander TG, Lavstsen T. The
820 Plasmodium falciparum var gene transcription strategy at the onset of blood stage
821 infection in a human volunteer. Parasitol Int. 2009 Dec;58(4):478–80.
- 822 37. Bachmann A, Petter M, Krumkamp R, Esen M, Held J, Scholz JAM, et al. Mosquito
823 Passage Dramatically Changes var Gene Expression in Controlled Human Plasmodium
824 falciparum Infections. Dzikowski R, editor. PLOS Pathog. 2016 Apr
825 12;12(4):e1005538.

- 826 38. Lavstsen T, Magistrado P, Hermesen CC, Salanti A, Jensen AT, Sauerwein R, et al.
827 Expression of Plasmodium falciparum erythrocyte membrane protein 1 in
828 experimentally infected humans. *Malar J*. 2005 Apr 27;4:21.
- 829 39. Simpson JA, Aarons L, Collins WE, Jeffery GM, White NJ. Population dynamics of
830 untreated Plasmodium falciparum malaria within the adult human host during the
831 expansion phase of the infection. *Parasitology* [Internet]. 2002 Mar [cited 2019 Mar
832 25];124(03). Available from:
833 http://www.journals.cambridge.org/abstract_S0031182001001202
- 834 40. Cheng Q, Gregor L, Stowers A, Lisa R-C, Alison C, Richard C, et al. Measurement of
835 Plasmodium Falciparum growth rates in vivo: a test of malaria vaccines. *Am J Trop*
836 *Med Hyg*. 1997;495–500.
- 837 41. Duncan CJA, Sheehy SH, Ewer KJ, Douglas AD, Collins KA, Halstead FD, et al. Impact
838 on Malaria Parasite Multiplication Rates in Infected Volunteers of the Protein-in-
839 Adjuvant Vaccine AMA1-C1/Alhydrogel+CPG 7909. Gregson A, editor. *PLoS ONE*.
840 2011 Jul 22;6(7):e22271.
- 841 42. Murray L, Stewart LB, Tarr SJ, Ahouidi AD, Diakite M, Amambua-Ngwa A, et al.
842 Multiplication rate variation in the human malaria parasite Plasmodium falciparum. *Sci*
843 *Rep* [Internet]. 2017 Dec [cited 2019 Mar 26];7(1). Available from:
844 <http://www.nature.com/articles/s41598-017-06295-9>
- 845 43. Abdi AI, Hodgson SH, Muthui MK, Kivisi CA, Kamuyu G, Kimani D, et al. Plasmodium
846 falciparum malaria parasite var gene expression is modified by host antibodies:
847 longitudinal evidence from controlled infections of Kenyan adults with varying natural
848 exposure. *BMC Infect Dis* [Internet]. 2017 Dec [cited 2019 Mar 31];17(1). Available
849 from: <http://bmcinfectdis.biomedcentral.com/articles/10.1186/s12879-017-2686-0>
- 850 44. Recker M, Nee S, Bull PC, Kinyanjui S, Marsh K, Newbold C, et al. Transient cross-
851 reactive immune responses can orchestrate antigenic variation in malaria. *Nature*. 2004
852 Jun;429(6991):555–8.
- 853 45. Klein EY, Graham AL, Llinás M, Levin S. Cross-Reactive Immune Responses as
854 Primary Drivers of Malaria Chronicity. Adams JH, editor. *Infect Immun*. 2014
855 Jan;82(1):140–51.
- 856 46. Rodriguez-Barraquer I, Arinaitwe E, Jagannathan P, Kamya MR, Rosenthal PJ, Rek J, et
857 al. Quantification of anti-parasite and anti- disease immunity to malaria as a function of
858 age and exposure. :20.
- 859 47. Maire N, Molineaux L, Smith T, Owusu-Agyei S, Ross A, Dietz K. A model for natural
860 immunity to asexual blood stages of Plasmodium falciparum malaria endemic areas.
861 *Am J Trop Med Hyg*. 2006 Aug 1;75(2_suppl):19–31.
- 862 48. Nkhoma SC, Trevino SG, Gorena KM, Nair S, Khoswe S, Jett C, et al. Co-transmission
863 of Related Malaria Parasite Lineages Shapes Within-Host Parasite Diversity. *Cell Host*
864 *Microbe*. 2020 Jan;27(1):93-103.e4.

- 865 49. Early AM, Lievens M, MacInnis BL, Ockenhouse CF, Volkman SK, Adjei S, et al. Host-
866 mediated selection impacts the diversity of *Plasmodium falciparum* antigens within
867 infections. *Nat Commun*. 2018 Dec;9(1):1381.
- 868 50. Bushman M, Antia R, Udhayakumar V, de Roode JC. Within-host competition can delay
869 evolution of drug resistance in malaria. Riley S, editor. *PLOS Biol*. 2018 Aug
870 21;16(8):e2005712.
- 871 51. de Roode JC, Helinski MEH, Anwar MA, Read AF. Dynamics of Multiple Infection and
872 Within-Host Competition in Genetically Diverse Malaria Infections. :12.
- 873 52. Gatton ML, Peters JM, Fowler EV, Cheng Q. Switching rates of *Plasmodium falciparum*
874 *var* genes: faster than we thought? *Trends Parasitol*. 2003 May;19(5):202–8.
- 875

Additional file

Mechanistic within-host models of the asexual *Plasmodium falciparum* infection: a review and analytical assessment

Authors:

Flavia Camponovo^{1,2,3}, Tamsin E. Lee^{1,2}, Jonathan Russell⁴, Lydia Burgert^{1,2}, Jaline Gerardin⁵, Melissa A. Penny^{1,2*}

¹ Swiss Tropical and Public Health Institute, Basel, Switzerland

² University of Basel, Basel, Switzerland

³ current address: Center for Communicable Disease Dynamics, Department of Epidemiology, Harvard T. H. Chan School of Public Health, Boston, MA 02115, USA

⁴ Institute of Disease Modeling, Bill & Melinda Gates Foundation, 500 5th Ave N, Seattle, WA 98109, USA

⁵ Department of Preventive Medicine and Institute for Global Health, Northwestern University, Chicago IL, USA

* corresponding author

Summary of each model

Molineaux *et al.* (1): The model was developed to reproduce spontaneously cured malaria infection observed in 35 patients of the malariatherapy dataset who were not treated throughout the course of the therapy. The primary aim of the model was to incorporate realistic host immune responses and parasite dynamics, and to eventually include the model in a population transmission model at a later date.

The model described by Molineaux *et al.* is the first model in which immune responses against infection were divided into three components, *i*) the innate immune response, *ii*) the variant specific immune response and *iii*) the general adaptive immune response (variant transcending) (for details see Table S2). It is a discrete model with a 2-day time step to align with the merozoite's 48 hour replication cycle, and the model allows for up to 50 variants of the parasite population. At each time step the observed parasite growth increases as a result of the intrinsic parasite multiplication rate and is reduced by the effect of the three immune responses (with each response ranging between 1 = no effect to 0 = maximum effect). Each infection begins with all 50 variants (denoted by $i = 1, 2, \dots, 50$) with initial densities set at 0, except one variant set at 0.1 PBRC/ μ l. At each time step parasites switch to different variants, with variant specific switching probabilities defined by a constant switching rate. The different probability of switching to each of the variants follows a geometric distribution and is modulated by the variant specific immune responses.

The innate immune response is thought to be triggered early in the infection (first few weeks), and its effect is proportional to the total parasite density at a given time, conditional on a host specific critical density. The variant specific immune response is triggered by the variant specific parasite density, effective after a certain delay (8 days), and persists with a decaying intensity. In addition, the switching mechanisms are controlled by the variant immune response, with the probability to switch to given variant increasing with high total immune responses against each of the 50 variants and decreasing with high immune response against that specific variant. The variant specific immune response, and the capacity of the parasite to switch to new variants, are thought to be a major cause for the different waves of parasitemia, and the chronic pattern of infection. The general adaptive immune response builds up slowly against the conserved part of the parasite, and acts against all variants of the parasite equally. It is effective after a delay (8 days), conditional on a host specific critical

density, and responds to the cumulative parasite density with no decay in time. The general adaptive immune response is assumed to be the main cause of infection clearance, and this is confirmed by simulations except for a few simulations with chronic infection a result of stochasticity in several variant growth rates (see Fig 4 in the main).

In this discrete model, the authors include both patient specific and stochastic parameters to represent the high variability in infection dynamics among the 35 malariatherapy patients (see parameters P_m and P_c , in Table S1). Variant specific parasite multiplication rates are drawn from a Normal distribution with a mean of 16 (truncated at a minimum of 1), leading to different multiplication rates for each of the 50 variants and for each simulation, but constant throughout the infection and different in each simulation. The inter-individual variability is captured by two patient specific parameters representing the critical densities for the innate immune response and the general adaptive immune response. The critical densities are calculated using the first local maximum density, and the length of the infection directly observed for each patient in the dataset.

Molineaux *et al.* additionally added a measurement error and thus were able to reproduce the 35 infections with their model by selecting, as a final step and not included in this analysis, one simulation from a pool of 50 simulations, a pool generated after trial and error, that best fit the min, median, max of the nine summary statistics, using χ^2 test, for each for the 35 patients. This final step makes it difficult to reproduce the authors selection, but general infection dynamics for each patient are possible to reproduce.

Johnston *et al.* (2): The model was directly adapted from Molineaux *et al.* in order to be included in an individual-based model (IBM), with four parameters re-fitted via bootstrapping method to fit the minmedian and max of the nine summary statistics as well as duration o infection (more details in Table S3). This transmission model was used to understand the human component of the reproductive number R_0 , and to investigate the impact of drug treatment (through Pharmacokinetic and Pharmacodynamic (PKPD) models) and drug resistance on transmission (2). To include an adapted Molineaux *et al.* model in a transmission model, they modified the within host model to avoid the two patient specific parameters. Instead, these parameters were drawn from appropriate distributions to maintain inter-individual variability. The authors re-parametrized the patient specific parameters by using the log Normal distribution (for estimates of the first local maximum density) and the Gompertz distribution (for estimates of the length of infection) defined in previously

published literature (3). To maintain the parasite multiplication rates in Johnston *et al.* within a smaller range, and thus a biologically more realistic range compared to Molineaux *et al.*, the Normal distribution was truncated not only at 1, but also on the upper end at 35.

In order to obtain a reasonable fit to the dataset following modification to the critical densities for the innate immune response and the general adaptive immune response, Johnston *et al.* re-fitted three additional parameters. All other parameters were fixed to values from Molineaux *et al.*. The refitted parameters are, *i*) the decay parameter of the acquired variant specific immune response (σ) was increased from 0.02 to 0.15, and *ii*) a constant (k_m) allowing the calculation of the critical density threshold used for the general adaptive immune response (P_m) was reduced from 0.04 to 0.025, and *iii*) a constant (k_c) allowing the calculation of the critical density threshold used for the innate immune response (P_c) was reduced from 0.2 to 0.164. By increasing the decay rate of the acquired variant specific immune response by almost ten-fold, Johnston *et al.* effectively increased infection length as an increased variant specific immunity decay rate (compared to Molineaux *et al.*) leads to a less efficient variant specific immune response. In contrast, parameters k_m and k_c in Johnston *et al.* are coupled to P_m and P_c and potentially increase the strength of the innate and general immune response (see Table S2 for full details).

Challenger *et al.* (4): Challenger *et al.* adapted the model from Johnston *et al.*, with the aim to assess the impact of treatment adherence and treatment failure (adding PKPD). The main adaptation of Johnston *et al.*, by Challenger *et al.* was reduction of the 50 variant specific parasite densities to a single total parasitemia, thereby reducing the number of equations from 50 to 1, simplifying the model and reducing computational time and memory requirements. The variant specific immune response in Challenger *et al.* is thus a function that represents the response to all variants instead of being the sum of responses to each variant. Early in the infection, the variant specific immune response is modeled similarly to the innate immune responses of Johnston *et al.* and Molineaux *et al.*, except for a different critical density threshold (constant for the innate immune response, stochastic for the variant specific immune response, see Table S2). During the time course of the infection, the variant specific immunity in this model responds not only to the parasite density eight days before (due to assumed delay in activation), but also to earlier time points. Thus Challenger *et al.*, in contrast to Molineaux *et al.* and Johnston *et al.*, implicitly assume immunological memory to

previously expressed variants and cross-reactivity (4), despite not tracking all 50 variants (see Fig. S1 and Table S2).

Since Challenger *et al.* do not track 50 variants, unlike Molineaux *et al.* and Johnston *et al.*, the model considers an overall multiplication rate across all variants expressed at each time. This overall multiplication rate is computed for each time step, drawn from a Normal distribution around 16 while being positively correlated to the previous time step, implying that this stochastic, but correlated, parasite multiplication rate is the result of the emergence and disappearance of variants during the time course of an infection (4).

The model of Challenger *et al.* was fitted to the same 35 malariatherapy patients as in Molineaux *et al.*, fitting the parameters of the overall variant specific immune response and the overall multiplication rate, and re-fitting the constant allowing the calculation of the critical density threshold for the general adaptive immunity (k_m). The authors used Markov chain Monte Carlo method u(Metropolis-Hasting algorithm) to generate random walks in parameter space and fitted the model to the nine summary statistics (see Table S3). A constant that allowed the calculation of the critical density threshold for the general adaptive immunity (k_m) was reduced from 0.0250 to 0.021 which leads to a slightly stronger general adaptive immune response in Challenger *et al.* compared to Molineaux *et al.*. Additionally, the critical density threshold of the innate immune response function (P_c) was drawn from a log Normal distribution with $\sigma = 1.2$ instead of $\sigma = 1.148$ as in the other models. All other parameters are identical to the model in Johnston *et al.*.

Gatton & Cheng (5): Gatton & Cheng (5) is a model adapted from a previously published probabilistic model of Paget-McNicol *et al.* (6). The model was fitted to the malariatherapy data differentiated by the *P. falciparum* I strain used. The model was fitted using sets of 100 simulations, altering 6 parameters in the model. They compared the model output to four variables, namely maximum parasitemia, number of days with fever, number of days with parasitemia higher than 10/microliter, and number of days with parasitemia higher than 10000/microliter (see Table S3).

As with Molineaux *et al.*, it tracks 50 different variant specific parasites, starts the infection with only one variant expressed, tracks the parasites in 2-day time steps, and includes three different types of immune responses. The model describes the total number of asexual parasites via a flowchart which acts more like a decision tree with triggers different equations

for given parasite numbers (5) (see equations in the Table S2). At each time step the parasites undergo replication with a multiplication rate of 16, and the probability of success of the replication is computed from Binomial distribution dependent on the general adaptive and variant specific immune response. Thus, in the absence of any immune response, the parasites have a constant growth rate of 16.

The innate immune response in Gatton & Cheng is activated after reaching a threshold and is assumed to increase with a higher number of parasites until a maximum effect is reached. The effect of the variant specific immune response is modeled as being inversely proportional to the number of antibodies produced, the latter being computed at each time step. The magnitude of the antibody response is dependent on whether this antibody has previously been produced during the infection, as well as cross-reactivity (so that an antibody response against a specific variant also has a small effect on all other variants). The general adapted immune response is only dependent on the time of infection, thus not changing with parasite numbers, nor does it differ between individuals (see Table S2). Additional biological differences between the model of Gatton *et al.* compared to Molineaux *et al.* and Johnston *et al.* is the switching mechanism from one variant to another, which in Molineaux *et al.* and Johnston *et al.* is assumed to depend on the variant specific immune response, whereas in Gatton & Cheng it is completely independent from the host's immune response. In addition, Gatton & Cheng assumes two populations of variants, either fast or slow switching, with 10 variants considered fast switching (rate ~ 0.5 -4.5%) and 40 in the slow switching group (rate ~ 9.10 -11.8 %) , compared to 0.02% in Molineaux *et al.* and Johnston *et al.*. Switching dynamics were previously investigated by the author (7) and based on *ex-vivo* analysis of var gene transcripts of parasites isolated two volunteers who underwent challenge infection (8).

Eckhoff (9): A summary and illustration of this model can be found on (10). This model has both discrete and continuous components, to represent discrete events such as schizont rupture in a two-day interval and the antibody response against merozoites, and to represent the continuous immune components acting on infected red blood cells (iRBCs). This model is more complex in the immune response mechanisms described, compared to the Molineaux *et al.* and Molineaux adapted models, as it explicitly includes antibody responses to PfEMP1 and with smaller effect to minor epitopes, it includes immunological memory of the antibody response, and it includes continuous and discrete immune responses.

The blood-stage immune response is divided into four components, namely the innate immune response, the antibody immune response against each PfEMP-1 variant, and each shared minor epitope, and the antibody immune response against merozoite proteins (such as MSP-1 and AMA-1). As for the Molineaux *et al.* and Molineaux adapted models, the innate immune response is assumed to limit the maximum parasite density (first peak). This innate immune response acts against both iRBCs (continuous component) and against ruptured schizonts (discrete component). Its effect is activated by a pyrogenic threshold, and it decreases with increased antibody levels. The antibody response is dependent on the capacity to generate specific antibodies, which depends on the concentration of the variant specific parasite and on the immune memory to the parasite. Similarly, to other models, the antibody response decays once the corresponding parasite population is absent, but the antibody production capacity keeps an immunological memory. Thus, once exposed again to the same variant, the antibody response will reach higher levels faster. The immune response against merozoite proteins has a similar effect as the general adaptive immune response in the other models. It increases in time and leads to a decrease of the parasite peaks amplitude in time. The PfEMP1 variant specific immune response eventually clears the infection.

Initially, the model was fitted to malariatherapy data, but contrary to Molineaux *et al.*, the dataset includes patients with reinfection (as memory of immune response is modeled) and the perturbed ones to avoid selection biases. Parameters are either assumed through literature, or fitted to the malariatherapy dataset (details in (9)). The model outputs were compared to the first parasite density peak, lower secondary peaks, and lower peaks after 100 days, the possibility of reinfection with homologous strains, the interval between peaks, and the distribution of measured durations (9). The model has been re-fitted more recently using field data (11), and re-calibrated parameters included the number of PfEMP1 variants the switching rate, the number of MSP variants in the overall parasite population, the fraction of merozoites inhibited by maximum MSP1-specific antibody level, the number of minor epitope variants, and the kill rate of infected red blood cells due to antibody response to minor epitopes. As described in (11), a Dirichlet-multinomial distribution was used to compare simulation data with field data (12,13).

Childs & Buckee (14): This is a deterministic discrete model with 2-day time steps. It tracks parasite population of 60 variants and includes four different immune mechanisms. The immune response includes innate, variant specific, general adaptive immune response, similar

to the other models, as well as a cross-reactive immune response. Parasite growth depends on the variant specific inherent multiplication rate, drawn from a Normal distribution, and parasite growth is limited by red blood cell availability. Similar to the other models, the innate immune response depends on the current number of parasites, the variant and cross-reactive immune response depend on the variant specific (or group of variants for the cross-reactive immune response) parasites, and the general immune response grows slowly during the course of an infection. Differing to the other models, the four immune responses are all capped by a maximum efficacy level, and the variant specific and cross-reactive immune response depend on the number of available immune cells. The cross-reactive immune response acts on groups of variants randomly grouped and pre-determined. The general immune response, instead of being dependent on time or cumulative parasite density like the other models, here increases each day that the number of parasites are above a certain threshold.

Because the main aim of this model was to understand the key assumptions of the biological mechanisms included in the mechanistic within host model, the model's main advantage compared to the others rely on the sensitivity analysis in the parameter values. Indeed, it is a deterministic model, but a wide range of values for all the parameters have been evaluated using the Latin Hypercube Sampling method. In addition, different switching networks, enabling parasites to switch from one variant to another, were evaluated.

Gurarie *et al.* (15): This is a discrete 2-day time step model. In this model there is a continuous production and loss of uninfected RBCs, which can become infected by the release of merozoites, and parasite replication is inhibited by two immune effectors, innate and adaptive. The merozoite invasion depends on available RBCs so that when the ratio between the number of merozoite and the number of available RBCs becomes large, merozoites start competing for available RBCs. Despite this assumption, it is not clear RBC availability is important for human *P. falciparum* infection. The innate immune response depends on the number of infected cells, activated after reaching a certain parasite density threshold level, and reaching a maximum clearance level. The adaptive immune response is triggered by the product of infected RBCs, and the combined effector pool of the innate and adaptive response, which is a way to allow for adaptive immune memory, and it also depends on an activation threshold. Similar to the other models, the adaptive immune response takes more time to develop but has a slower decay time compared to the innate immune response.

Rather than explicitly modelling the different variant populations, the variant switching dynamics, and variant specific immune response, such as in other models, the model greatly simplifies the equations by using proxies of the more complex underlying mechanisms. First the model only includes innate and adaptive immune responses, making no distinction between the variant specific and general adaptive immune response. Second the parasite population is taken as a whole and does not differentiate between the variant-specific populations. Nevertheless, the variant switching and resulting decrease in an effective adaptive immune response is implicitly accounted for by forcing “random falls” at each replication cycle (where potentially parasites switched to a new variant) of the effective adaptive immune response. To implicitly account for the variant-transcending immune response, the amplitude of the random falls of the effective adaptive immune response decrease in time.

The model was fitted using the malariatherapy data (from 122 patients), and each malariatherapy patient was considered a random realization of a stochastic process. The fitting process was done in two steps to fit the first parasitemia peak assumed deterministic and a second stochastic step for parasitemia post first peak. The model outcome was compared to minimum and maximum of parasite density time-series for each patient, and 50 simulations per patient were selected as an ensemble of best choices (Table S3). The calibration process of the model resulted in a range of parameter values that can be randomly chosen at each realization, and thus allow for variability in the parasite dynamics as observed in the malariatherapy dataset. These parameters relate to the invasion probability, the replication of parasites, immune response efficiencies and activation thresholds, and the assumed antigenically distinct variant clusters.

McKenzie & Bossert (16) : This model is the only model studied here that uses differential equations rather than discrete equations to represent the malaria within host dynamics. The model includes merozoite replication and conversion of parasites into gametocytes and includes the effect of two types of immune responses, innate and adaptive. There is no distinction of variant specific parasites. Both immune responses are stimulated by the asexual density, with a stronger stimulus of the innate effectors, but the dynamic of the innate effectors assume the decay and the removal of the effectors, while the adaptive immune response grows with the asexual parasite density and has no decay or removal in time (note

268 that the equation for the adaptive effectors include a decay component, but its parameter $w =$
269 0 in (16).).

270 Although not explored in this study, the model tracks different genotypes, includes cross-
271 reactivity, and in addition, investigated several aspect of gametocyte dynamics. Cross-
272 reactivity is included by allowing for immune responses to one genotype to be stimulated by
273 the asexual parasite density of another genotype.

274 The model was fitted to data from 63 malariatherapy patients who were inoculated with the
275 McLendon strain, including only the parasite densities in time before any drug was
276 administered. The model was fitted to data from each of the 63 patients individually, using
277 the steepest-descent algorithm and comparing model outputs to parasite density time-series
278 (Table S3), and an average of the parameter values was reported and used for their
279 transmission model.

281

282 **Figure S1: Schematic illustration of an infection and variant specific immune responses at**
 283 **a given time point from models Molineaux et al., Johnston et al., and Challenger et al..**

284 Example illustration of total parasite density in time (black) with an example of a single
 285 variant parasite density in orange. The parasite density affecting the variant specific immune
 286 response is represented by the coloured area in blue for Molineaux et al., in purple for
 287 Johnston et al., and in green for two examples at two different time points for Challenger et
 288 al.. At a given time point, represented by a red dot, the variant specific immune response in
 289 the Molineaux et al. (M) and Johnston et al. (J) model depend on the variant specific parasite
 290 density (orange) from eight days prior to the time point, and the effect of the parasite density
 291 decreases in time, with Molineaux et al. assuming a slower decay rate than Johnston et al..
 292 For Challenger et al. (C), the total parasite density (black) in a given time frame eight days
 293 prior to the time point affect the variant specific immune response, with the time frame
 294 increasing further along in the infection, implicitly including immune memory, here
 295 represented by an example of two time points (red).

Table S1 : Summary statistics of the observed malariatherapy data and the models. Summary statistics from the simulation are shown in the first row, and the published results in the second row in italics. Source of published statistics: data [1], Johnston *et al.*(2), Challenger *et al.*(4), Gatton & Cheng (5).

	Data			Molineaux <i>et al</i>			Johnston <i>et al</i>			Challenger <i>et al</i>			Gatton & Cheng			Eckhoff		
	med	min	max	med	min	max	med	min	max	med	min	max	med	min	max	med	min	max
initial slope	0.49	0.19	0.87	0.50	0.22	0.74	0.52	0.19	0.74	0.49	0.15	0.72	0.47	0.28	0.56	0.35	0.32	0.39
				<i>0.49</i>	<i>0.19</i>	<i>0.87</i>	<i>0.52</i>	<i>0.24</i>	<i>0.75</i>	<i>0.49</i>	<i>0.25</i>	<i>0.71</i>						
log10(density) peaks	4.79	3.37	5.66	4.91	4.46	5.30	4.73	3.55	5.58	4.66	3.49	5.56	4.93	4.49	5.54	4.80	4.76	4.84
				<i>4.79</i>	<i>3.37</i>	<i>5.66</i>	<i>4.78</i>	<i>3.69</i>	<i>5.67</i>	<i>4.77</i>	<i>3.57</i>	<i>5.61</i>	<i>4.81</i>	<i>4.47</i>	<i>5.31</i>			
n peaks	10.00	2.00	15.00	5.83	3.83	15.49	9.19	2.20	16.74	7.31	1.20	16.23	5.86	1.03	11.66	6.71	3.37	14.54
				<i>10.00</i>	<i>2.00</i>	<i>17.00</i>	<i>9.00</i>	<i>2.00</i>	<i>17.00</i>	<i>7.70</i>	<i>1.70</i>	<i>15.50</i>	<i>10.00</i>	<i>1.00</i>	<i>27.00</i>			
slope peaks	-0.01	-0.07	0.00	-0.02	-0.05	0.00	-0.02	-0.08	-0.01	-0.02	-0.07	0.00	-0.01	-0.03	0.01	-0.04	-0.07	-0.02
				<i>-0.01</i>	<i>-0.07</i>	<i>0.00</i>	<i>-0.02</i>	<i>-0.09</i>	<i>-0.01</i>	<i>-0.01</i>	<i>-0.03</i>	<i>0.00</i>	<i>-0.01</i>	<i>-0.03</i>	<i>-0.01</i>			
geo. mean peak interval	20.48	14.40	77.77	16.47	10.95	39.61	22.40	14.19	46.77	22.41	12.31	57.67	20.89	13.55	31.97	23.56	15.51	42.45
				<i>20.00</i>	<i>14.40</i>	<i>77.80</i>	<i>14.60</i>	<i>1.50</i>	<i>28.40</i>	<i>22.80</i>	<i>12.20</i>	<i>61.00</i>	<i>22.00</i>	<i>14.20</i>	<i>29.30</i>			
sd peak interval	0.20	0.03	0.47	0.17	0.03	0.50	0.31	0.10	0.57	0.21	0.05	0.38	0.19	0.03	0.29	0.25	0.08	0.35
				<i>0.20</i>	<i>0.03</i>	<i>0.47</i>	<i>0.31</i>	<i>0.04</i>	<i>0.56</i>	<i>0.22</i>	<i>0.03</i>	<i>0.48</i>	<i>0.22</i>	<i>0.07</i>	<i>0.29</i>			
prop. + 1st half	0.88	0.37	1.00	0.86	0.25	0.95	1.00	0.69	1.00	1.00	0.35	1.00	0.90	0.64	1.00	0.75	0.37	1
				<i>0.88</i>	<i>0.40</i>	<i>1.00</i>	<i>0.97</i>	<i>0.57</i>	<i>1.00</i>	<i>0.97</i>	<i>0.46</i>	<i>1.00</i>	<i>0.67</i>	<i>0.48</i>	<i>1.00</i>			
prop. + 2nd half	0.45	0.07	0.93	0.33	0.00	0.90	0.66	0.12	1.00	0.99	0.21	1.00	0.75	0.52	1.00	0.28	0.09	0.88
				<i>0.46</i>	<i>0.08</i>	<i>0.94</i>	<i>0.58</i>	<i>0.12</i>	<i>1.00</i>	<i>0.79</i>	<i>0.10</i>	<i>1.00</i>	<i>0.61</i>	<i>0.37</i>	<i>1.00</i>			
last + day	215	37	405	142	74	599	182	37	366	123	24	257	129	20	265	177	82	439
				<i>215</i>	<i>37</i>	<i>405</i>	<i>193</i>	<i>38</i>	<i>404</i>	<i>198</i>	<i>39</i>	<i>409</i>	<i>239</i>	<i>10</i>	<i>590</i>

Figure S2: Immune responses, multiplication rates and asexual parasite densities in different models. Each panel shows, from top to bottom, 1. the effect of the innate immune response, 2. the effect of the variant specific immune response (see methods for calculations), 3. the effect of the general adaptive immune response, 4. the net effect of the product of the three immune responses, 5. the average (across variants, see methods) multiplication rate, 6. the log10 asexual density and 7. the product of the average multiplication rate with the net effect of the immune response. X-axis represents days of infection, solid line the median, shaded area the interquartile range (Q25-Q75) and the gray lines the minimum and maximum resulting from the 1750 simulations. The horizontal dashed green line represents an average multiplication rate of 16, the horizontal dashed black line indicate the threshold of positive density (10PBRC/ μ l). Results are shown for **a)** Molineaux *et al.*, **b)** Johnston *et al.*, and **c)** Challenger *et al.*, **d)** Gatton & Cheng, and **e)** Eckhoff

Table S2: Model equations

Within-host mechanistic models		
Molineaux <i>et al.</i> (1) and Molineaux adapted models (2,4)	Gatton & Cheng model (5)	Eckhoff (9)
Parasite dynamics		
<p><i>Parasite replication, influenced by immune responses, and antigenic variation</i></p> <ul style="list-style-type: none"> Molineaux <i>et al.</i> and Johnston <i>et al.</i> $P_i(t+2)' = \left((1-s)P_i(t) + sp_{i(t)} \sum_{j=1}^v P_j(t) \right) m_i S_c(t) S_i(t) S_m(t)$ <ul style="list-style-type: none"> Challenger <i>et al.</i> $P(t+2) = m(t) S_c(t) S_v(t) S_m(t) P(t)$ <p><i>Parasite density</i></p> <ul style="list-style-type: none"> Molineaux <i>et al.</i> and Johnston <i>et al.</i> $P_c(t) = \sum_{i=1}^v P_i(t)$ $P_i(t+2) = \begin{cases} P_i(t+2)' & \text{if } P_i(t+2)' \geq 10^{-5} \\ 0 & \text{otherwise} \end{cases}$	<p><i>Number of parasites</i></p> $X_t = \sum_{i=1}^{50} X_{t,i}$ $X_t = \begin{cases} X_t & \text{if } X_t \geq 1 \\ 0 & \text{otherwise} \end{cases}$ <p><i>Parasite antigenic variation</i></p> $X_{t,i} = X_{t,i} + st_{t,i} - sw_{t,i}$ <p><i>Parasite replication, influenced by immune responses</i></p> $X_{t+1,i} = \text{Bi}(16X_{t,j}, (1-m_t)/Ab_{t,i})$ <ul style="list-style-type: none"> If $X_t > \text{NSI threshold } (T)$: $X_{t,i} = \begin{cases} \text{Bi}\left(X_{t,i}, \exp\left(-k * \frac{X_t - T}{T}\right)\right) & \text{if } k(X_t - T) \leq 10 \\ \text{Bi}(X_{t,i}, \exp(-10)) & \text{if } k(X_t - T) > 10 \end{cases}$	<p>$t_{\text{asexual}} = T_{\text{asexual}}$, and $t_{\text{asexual},n+1} = t_{\text{asexual},n} - \Delta t$ defines a 48h timer for including both continuous and discrete events.</p> <p><i>Concentration per microliter of parasites expressing antigen i:</i></p> $X_i = N_i / (\text{number of microliters of blood})$ <p><i>Number of IRBCs of antigen n created by previous generation expressing antigen n</i></p> $N_n^1 = \left((1 - k_{\text{gametocyte}}) N_n - \sum_{n=1}^{\text{nantigenswitch}} N_{n+1,n} \right) N_{\text{IRBCmerozoites}} Z_{MS}$ <p><i>For all n, i=1 to n_{antigenswitch}, add in switching IRBCs</i></p> $N_{n+i}^1 = N_{n+i,n} N_{\text{IRBCmerozoites}} Z_{MS}$ <p><i>Number of IRBCs expressing antigen i whose merozoites will create IRBCs in the next generation n+1 expressing same antigen i</i></p> $N_{i,n+1} = N_{i,n} - \text{Binomial}(N_{i,n}, P_{\text{kill},i})$ $P_{\text{kill},i} = 1 - \exp\left(-\Delta t \left(\frac{C_{\text{innate}} Y_{\text{fever}}}{1 + Y_{\text{fever}}} + C_{\text{antibody}} (Y_{\text{antibody},i} + Y_{\text{Minorepitope},i} C_{\text{MinorMod}}) \right)\right)$
Antigenic switch		

<ul style="list-style-type: none"> Molineaux <i>et al.</i> and Johnston <i>et al</i> $p_i(t) = \begin{cases} 0 & \text{if } S_i(t) < 0.1 \\ \frac{q^i S_i(t)}{\sum_{j=1}^v q^j S_j(t)} & \text{otherwise} \end{cases}$	$st_{t,i} = \sum_{j=1}^{50} Bi(X_{t,j}, 0.18p_i / \sum_{i=1}^{50} p_i)$ $sw_{t,i} = \sum_{j=1}^{50} Bi(X_{t,i}, 0.18p_j / \sum_{i=1}^{50} p_i)$ $p_i = \begin{cases} 0 & \text{for var 1} \\ 1 & \text{for var 2} \\ \frac{p_{i-1}}{1.3} & \text{for var 3 to } c \\ \frac{p_{i-1}}{1 * 10^7} & \text{for var } (c + 1) \\ \frac{p_{i-1}}{1.18} & \text{for var } (c + 2) \text{ to } 50 \end{cases}$	<p>Number of IRBCs of antigen n switching to express antigen $n+i$</p> $N_{n+i,n} = \text{Poisson}(K_{\text{antigen}} N_n), 1 \leq i \leq n_{\text{antigenswitch}}$
Immune responses		
<p><i>innate</i></p> $S_c(t) = \left(1 + \left(\frac{P_c(t)}{P_c^*}\right)^{\kappa_c}\right)^{-1}$ <p><i>variant specific</i></p> <ul style="list-style-type: none"> Molineaux <i>et al.</i> and Johnston <i>et al</i> $S_i(t) = \left(1 + \left(\frac{\sum_{\tau=0}^{t-\delta_v} P_i(\tau) e^{-\sigma(t-\tau-\delta_v)}}{P_v^*}\right)^{\kappa_v}\right)^{-1}$ <ul style="list-style-type: none"> Challenger <i>et al</i> $S_v(t) = \left(1 + \left(\frac{\sum_{\tau=f(t)}^{t-8} P(\tau)}{P_{v2}^*}\right)^{\kappa_v}\right)^{-1}$	<p><i>innate</i></p> $T = \begin{cases} 1/SF * 10^{0.271t+1.6864+N(0,0.3)} & \text{if } t \leq 3 \\ 1/SF * 10^{3.39+N(0,0.3)} & \text{if } t > 3 \end{cases}$ <p><i>anti-PfEMP1</i></p> <ul style="list-style-type: none"> If $X_{t,i} \geq 6 * 10^7$ for the first time in the last 20 days Trigger antibody for variant i $s_i = t + 4$ $A_i = \begin{cases} N(\alpha, 100) & \text{for the first Ab produced} \\ N(\alpha + 200, 100) & \text{otherwise} \end{cases}$ $B_i = N(\psi, 0.07)$ <ul style="list-style-type: none"> Calculate amount of antibody present for each variant 	<p><i>innate</i></p> $\begin{cases} \text{for } t_{\text{asexual}} > 0 : \frac{dY_{\text{innate}}}{dt} = \frac{1}{\tau_{\text{innate}}} \frac{\sum_i X_i (1 - Y_{\text{antibody},i})}{\sum_i X_i (1 - Y_{\text{antibody},i}) + X_{50,\text{innate}}} \\ \text{for } t_{\text{asexual}} = 0 : \Delta Y_{\text{innate}} = \frac{\sum X_{\text{schizont}}}{\sum X_{\text{schizont}} + X_{50,\text{innate}}} \end{cases}$ $Y_{\text{fever}} = k_{\text{fever}} Y_{\text{innate}}$ <p><i>variant specific</i></p> <p>For $i=1$ to 50, if $X_i > 0$</p> $\frac{dY_{\text{capacity},i}}{dt} = \begin{cases} \frac{k_{\text{pfempminor}}}{\tau_{\text{capacity}}} \frac{X_i + k_{\text{antibody,min}} X_{50,\text{antibody}}}{X_i + X_{50,\text{antibody}}} (1 - Y_{\text{capacity},i}), Y_{\text{capacity},i} < 0.4 \\ \frac{1}{\tau_{\text{hyperimmunity}}} (1 - Y_{\text{capacity},i}), Y_{\text{capacity},i} \geq 0.4 \end{cases}$ $k_{\text{pfempminor}} = \begin{cases} 1 & \text{for PfEMP1} \\ k_{\text{minormod}} & \text{for minor epitopes} \end{cases}$

<p><i>Variant transcending</i></p> $S_m(t) = (1 - \beta) \left(1 + \left(\frac{\sum_{\tau=0}^{t-\delta_m} \hat{P}_c(\tau) e^{-\rho(t-\tau-\delta_m)}}{P_v^*} \right)^{\kappa_m} \right)^{-1} + \beta$ $\hat{P}_c(t) = \begin{cases} P_c(t) & \text{if } P_c(t) < C \\ C & \text{otherwise} \end{cases}$ $P_c^*(t) = k_c * (\text{first local max. density})$ $P_m^*(t) = k_m * [(\text{last pos. day}) - (\text{first pos. day})]$	$Ab_{t,i} = \begin{cases} A_i z_i e_i^{-Bz_i} & \text{if } t > s_i \\ 1 & \text{if } t \leq s_i \text{ and } Ab_{t,j} = 1 \text{ for all } j \\ 1.05 & \text{if } t \leq s_i \text{ and } Ab_{t,j} > 1 \text{ for any } j \end{cases}$ $z_i = (2t - s_i)/30$ <p><i>General adaptive</i></p> $m_t = m_0 + 0.5/(1 + \exp(-(2t - 30)/6))$	$\frac{dY_{antibody,i}}{dt} = \frac{1}{\tau_{abprod}} (Y_{capacity,i} - Y_{antibody,i}), Y_{capacity,i} > 0.3$ <p>For i=1 to 50, if $X_i = 0$</p> $\frac{dY_{capacity,i}}{dt} = -\frac{1}{\tau_{capdecay}} (Y_{capacity,i} - Y_{memory}), Y_{capacity,i} > Y_{memory}$ $\frac{dY_{antibody,i}}{dt} = -\frac{1}{\tau_{abdecay}} Y_{antibody,i}$ <p><i>Anti-MSP</i></p> $\text{if } t_{asexual} = 0$ $\Delta Y_{MSP} = K_{MSP} \frac{\sum X_{schizont}}{\sum X_{schizont} + X_{50,antibody}} (1 - Y_{MSP})$ $Z_{MS} = (1 - C_{merozoite} Y_{antibody,MSP})$
Variables		
<p>$P_i(t)$ = density of variant i, as PRBC/μl blood</p> <p>$P_c(t)$ = total parasite density, as PRBC/μl blood</p> <ul style="list-style-type: none"> Molineaux <i>et al.</i> and Johnston <i>et al.</i> <p>$p_i(t)$ = probability that a switching PBRC switches to variant i</p> <p>$S_c(t), S_i(t), S_m(t)$ = probability that a parasite of variant i escapes control by the innate immune response, acquired variant-specific immune response, and acquired variant-transcending immune response, respectively, in the interval $(t, t+2)$</p>	<p>$X_{t,i}$ = number of parasites of variant i</p> <p>X_t = total number of parasites</p> <p>$st_{t,i}$ = number of parasites switching to variant i</p> <p>$sw_{t,i}$ = number of parasites switching from variant i</p> <p>p_i = switch rate</p> <p>T, Ab_{ti}, m_t = innate immunity, anti-PfEMP1 antibodies, clonal immunity</p>	<p>N_n = number of IRBCs expressing antigen n</p> <p>$N_{n,n+i}$ = number of IRBCs expressing antigen n whose merozoites will create IRBC's in the next generation expressing antigen n+i</p> <p>N_n^1 = number of IRBCs in the new asexual cycle expressing antigen i</p> <p>X_i = Concentration per microliter of parasites expressing antigen i</p> <p>Y_{innate} = Level of pro-inflammatory cytokines</p> <p>Y_{fever} = Level of fever due to pro-inflammatory cytokines</p>

<ul style="list-style-type: none"> Challenger <i>et al</i> <p>$S_c(t), S_v(t), S_m(t)$ = probability that a parasite escapes control by the innate immune response, acquired variant-specific immune response, and acquired variant-transcending immune response, respectively, in the interval (t,t+2)</p>		<p>$Y_{antibody,i}$ = Level of antibodies specific to antigen i</p> <p>$Y_{capacity,i}$ = Variable representing changing capacity to produce antibodies specific to antigen i</p>
Parameters		
<p>v = number of variants per clone</p> <p>s = fraction of parasites switching among variants per two-day</p> <p>q = parameter of the geometric distribution of switching probabilities</p> <p>P_c^*, P_m^* = two host-specific critical densities</p> <p>k_c, k_m = two constants allowing calculation of P_c^*, P_m^* from host specific data</p> <p>P_v^* = critical density of a variant, common to all variants</p> <p>$\kappa_c, \kappa_v, \kappa_m$ = stiffness parameters for a saturation of innate immune response, acquired variant-specific immune response, and acquired variant-transcending immune response</p> <p>C = maximum daily antigenic stimulus, per μl, of the acquired variant-transcending immune response</p> <p>σ = decay parameters, per day, of the acquired variant-specific immune response</p> <p>δ_v, δ_m = delay parameters, in days, of the acquired variant-specific and variant transcending immune response, respectively</p> <p>β = maximum value of S_m</p>	<p>Switching parameters:</p> <ul style="list-style-type: none"> c; number of ‘fast’ switching <i>var</i> genes <p>Non specific immunity</p> <ul style="list-style-type: none"> SF, scaling factor correcting for difference between onset of NSI and pyrogenic threshold k, feedback constant for sensitivity of parasites to NSI response <p>Specific immunity</p> <ul style="list-style-type: none"> m_0 probability of parasites being killed by specific immunity at start of blood-stage infection <p>Anti-PfEMP1 immunity</p> <ul style="list-style-type: none"> α, parameter influencing magnitude of antibody response Ψ (months⁻¹), reciprocal of time to antibody peak 	<p>Immunological:</p> <p>$X_{50,innate}$ = parasitemia at which innate immune response is half of maximum</p> <p>$X_{50,capacity}$ = parasitemia at which antibody immune response is half of maximum</p> <p>τ_{innate} = inverse of maximum immune response rate</p> <p>$\tau_{capacity}$ = inverse of maximum antibody response rate</p> <p>$\tau_{hyperimmunity}$ = inverse of development of hyperimmunity</p> <p>$k_{antibodymin}$ = minimum antibody response to antigen</p> <p>$k_{minormod}$ = modification of response rate for minor epitopes</p> <p>C_{innate} = rate at which innate immune response kills IRBCs</p> <p>$C_{antibody}$ = rate at which specific antibody immune response kills IRBCs</p> <p>$C_{minormod}$ = modification of antibody kill rate for minor epitopes</p> <p>$C_{merozoite}$ = maximum blocking of merozoite invasion by MSP antibodies</p> <p>K_{MSP} = per cycle growth rate of MSP antibody response</p>

$m_i \sim N(\mu_m, \sigma_m^2)$ truncated to ensure $m_i \geq 1$ (Molineaux <i>et al</i>) or $35 \geq m_i \geq 1$ (Johnston <i>et al</i>) : basic multiplication factor, per two-day cycle, of variant i ; $m \sim N(\mu, \sigma), \frac{(m(t)-\mu)(m(t-\theta)-\mu)}{\sigma^2} = g^\theta, 0 < g < 1$: average growth rate at time t		Y_{memory} = immunological memory level $T_{hyperimmunity}$ = duration of hyperimmunity after removal of antigen Parasitological: $N_{IRBCmerozoites}$ = Merozoites per IRBC schizont $T_{asexual}$ = Duration of asexual cycle $N_{variants}$ = Number of PfEMP-1 variants per clone $N_{minorepitopes}$ = Number of minor epitopes per clone $K_{antigen}$ = PfEMP-1 switch rate $n_{antigenswitch}$ = number of non-suppressed available variants per IRBC
Comparing immune response effects between Molineaux <i>et al.</i> and Molineaux <i>adapted</i> models with Gatton <i>et al.</i> and Eckhoff		
S_c	<ul style="list-style-type: none"> effect of the innate immune response $\exp\left(-\frac{k(X_t - T)}{T}\right)$	$\exp\left(-C_{innate} \frac{k_{fever} Y_{innate}}{1 + k_{fever} Y_{innate}}\right)$
$S_{v,i}$	<ul style="list-style-type: none"> effect of the variant specific immune response $1/Ab_{t,i}$	$\exp(-C_{antibody}(Y_{antibody} + Y_{minorepitope} c_{MinorMod}))$
S_m	<ul style="list-style-type: none"> effect of the general adaptive immune response $1-m(t)$	$Z_{MS} = (1 - C_{merozoite} Y_{antibody, MSP})$
Within-host mechanistic models		
Childs & Buckee (14)	Gurarie <i>et al</i> (15)	McKenzie & Bossert (16)
Parasite dynamics		

<p>Number of parasites, dependent on growth and immune responses</p> $P_i(t+1) = g_i(t+1)I(t+1)\Gamma_{VS_i}(t+1)\Gamma_{CR_i}(t+1)M(t+1),$ <p>Parasite growth, dependent on intrinsic growth rate and inherent switching between variants, limited by red blood cells availability</p> $g_i(t+1) = \left(1 - \exp\left(-\frac{K(t)}{\sum_j p_j(t)}\right)\right) \left[\gamma_i p_i(t)(1 - \omega_i) + \omega_i \sum_{j \neq i} \gamma_j \beta_{ji} p_j(t) \right]$	<p>Uninfected red blood cells, depend on homeostatic production and loss of red blood cells, and the loss due to merozoite invasion</p> $x' = (1 - \delta)x_0 + \delta x - \rho\left(\frac{M}{x}\right)x$ <p>Infected red blood cells, depend on combined level of innate and adaptive immune response, and on merozoite invasion</p> $y' = 2^{-(a+b)}\rho\left(\frac{M}{x}\right)x$ <p>Merozoite equation depends on the effective replication rate of the parasite: $M = ry + S$</p> <p>Effective probability of invasion decreases according to:</p> $\rho(z) = 1 - e^{-z}$ $z = M/x$	<p>Asexual parasite density, depend on daily replication of asexual parasite, daily conversion into gametocytes, and the effect of immune response:</p> $\frac{dM_u}{dt} = (a_u - z_u - c_u I - \Sigma b_{u,v} J_v)M_u$
Antigenic switch		
$g_i(t+1) \propto \omega_i \sum_{j \neq i} \gamma_j \beta_{ji} p_j(t)$	-	-
Immune responses		
<p>innate</p> $I(t+1) = \min\left(E_I, \left(\frac{1 + \sum_i p_i(t)}{1 + \sum_i p_i(t) + C_I}\right) E_I\right)$ <p>variant specific</p> <ul style="list-style-type: none"> Dynamics of immune cells, depend on pre-existing cells, expansion when variant specific parasites in large quantities, decay, and restricted by total number of immune cells available 	<p>Innate effectors, stimulation triggered by parasite level relative to threshold A, and has a short life span</p> $a' = f_a \phi_a\left(\frac{y}{A}\right) + \sigma_a a$ <p>Adaptive effectors, stimulation triggered by parasite level relative to threshold B, and has a longer life span</p> $b' = q f_b \phi_b\left(\frac{y(a+b)}{B}\right) + \sigma_b b$	<p>innate immune effectors</p> $\frac{dI}{dt} = \Sigma s_v M_v - I \Sigma k_v M_v - qI$ <p>acquired immune effectors:</p> $\frac{dJ_u}{dt} = \Sigma r_{u,v} M_v - w_u J_u$

$VS_i(t+1) = VS_i(t) \left(1 + \pi_{VS} \exp \left(-\frac{\psi_{VS}}{p_i(t-\tau)+1} \right) \right) \left(1 - \mu_{VS} \left(1 - \exp \left(-\frac{\psi_{VS}}{p_i(t)+1} \right) \right) \right) \left(1 - \exp \left(-\frac{K_{Imm}}{\sum_j VS_j(t)} \right) \right)$ <ul style="list-style-type: none"> Effectiveness of response, depend on relative amount of parasite variants and specific immune cells $\Gamma_{VS_i}(t+1) = E_{VS} \left(1 - \exp \left(-\frac{1+g_i(t)}{VS_i(t)} \right) \right)$ <p>cross-reactive:</p> <ul style="list-style-type: none"> Dynamics of immune cells, depend on pre-existing cells, expansion when group of variant specific parasites in large quantities, decay, and restricted by total number of immune cells available $CR_i(t+1) = CR_i(t) \left(1 + \pi_{CR} \exp \left(-\frac{\psi_{CR}}{1 + \sum_{j \sim i} p_i(t-\tau)} \right) \right) \left(1 - \mu_{CR} \left(1 - \exp \left(-\frac{\psi_{CR}}{1 + \sum_{j \sim i} p_i(t)} \right) \right) \right) \left(1 - \exp \left(-\frac{K_{Imm}}{\sum_j CR_j(t)} \right) \right)$ <ul style="list-style-type: none"> Effectiveness of response, depend on relative amount of a group of parasite variants and specific immune cells $\Gamma_{CR_i}(t+1) = E_{CR} \left(1 - \exp \left(-\frac{1 + \sum_{j \sim i} g_i(t)}{CR_i(t)} \right) \right)$ <p>Variant transcending</p>	<ul style="list-style-type: none"> Antigenic variation accounted for by random falls in effector, q_0 an exponential function with base: $q_0 = 2^{-1/m} < 1$	
---	---	--

$M(t+1) = \min \left(E_M, \frac{1 + \sum_t \chi_t}{1 + C_M + \sum_t \chi_t} E_M \right)$ $\chi_t = \begin{cases} 1, & \text{if } \sum_i p_i(t) > 10^7 \\ 0 & \text{otherwise} \end{cases}$		
Variables		
<p>$P_i(t)$ = overall number of parasites of the ith antigenic variant</p> <p>$g_1(t)$ = parasite growth, in the absence of any immune response</p> <p>$I(t), f_{VS_i}, f_{CR_i}, M(t)$ = effectiveness of the innate, variant specific, cross-reactive, and general immune response, respectively</p> <p>CR_i, VS_i = dynamics of the variant specific, and cross-reactive immune cells, respectively.</p>	<p>x = uninfected RBC measured per microliter of blood</p> <p>y = infected RBC measured per microliter of blood</p> <p>M = number of merozoites released (a result of $y(t)$)</p> <p>a, b = dimensionless variables representing innate and adaptive immune effectors, respectively</p>	<p>M = asexual forms</p> <p>J = acquired-immunity effectors</p> <p>I = innate-immunity effectors</p> <p>subscript v : different genotypes</p>
Parameters		
<p>Immunological:</p> <p>E_I, E_{VS}, E_{CR}, E_M = maximum efficacy of innate, variant specific, cross-reactive, and general immune response, respectively</p> <p>$C_I, \psi_{VS}, \psi_{CR}, C_M$ = half-maximal activation of innate, variant specific, cross-reactive, and general immune response, respectively</p> <p>$K(0), K_{Imm}$ = restriction of total number of red blood cells, and immune cells, respectively</p> <p>μ_{VS}, μ_{CR} = maximum decay rate of variant-specific, and cross-reactive immune cells, respectively</p> <p>π_{VS}, π_{CR} = maximum growth rate of variant-specific, and cross-reactive immune cells, respectively</p>	<p>Immunological:</p> <p>A, B = Threshold to trigger innate and adaptive immune effectors, respectively</p> <p>ϕ_a, ϕ_b = Hill function defining innate and adaptive immune stimulation, respectively</p> <p>f_a, f_b = maximal stimulation efficiency of innate and adaptive immune response, respectively</p> <p>$a_M = \frac{f_a}{1-\sigma_a}, b_M = \frac{f_b}{1-\sigma_b}$ = maximal clearance levels of innate and adaptive immune effectors, respectively. $a_M + b_M \gg \log(r)$</p> <p>δ_a, δ_b = survival rate per cycle of innate and adaptive effectors, respectively</p>	<p>Immunological:</p> <p>c, b = daily removal rate of asexual forms by innate-immune, and acquired immune response effectors, respectively</p> <p>s, r = rate of stimulation of the innate immune, and acquired immune response (effectors per asexual form)</p> <p>k = removal rate of innate-immune effectors (effectors per effector asexual form)</p> <p>q, w = decay rate of innate-immune, and acquired immune response effectors, respectively</p> <p>Parasitological:</p> <p>a = daily replication rate of asexual blood forms,</p>

τ = delay of adaptive immune response activation (days) Parasitological: γ_i = intrinsic growth rate of variant i ω_i = percentage switching to a new variant from variant i β_{ji} = switching probability from variant i to variant j	Parasitological: r = effective replication rate p = probability of a merozoite to invade an uninfected RBC m = number of antigenically distinct variant clusters x_0 = normal concentration of uninfected RBC	z = conversion rate of asexual forms to gametocytes
--	---	---

Table S2: Model fitting, as described in the initial publications. Fitting methods and data might have been modified subsequently.

Models	Molineaux <i>et al.</i>	Johnston <i>et al.</i>	Challenger <i>et al.</i>	Gatton <i>et al.</i>	Childs & Buckee.	Eckhoff	McKenzie & Bossert	Gurarie <i>et al.</i>
Fitting method	Informed trial and error (no systematic fitting) to find the best set of parameters. In a second step each patient was simulated 50 times (with different multiplication factors), and χ^2 was used to identify best patient specific match	Bootstrapping, not all parameter space explored. The model was run 1,000 times and 50 samples of 50 runs each were selected. Goodness-of-fit, was assessed with relative errors between model outputs tested outcome	Same than Johnston <i>et al.</i> , but with MCMC using Metropolis-Hasting algorithm to generate random walks in parameter space	Fitted to the patient data using sets of 100 simulations, altering the 6 parameters until the distribution of simulations did not differ significantly to that of the patient data.	Stochastic sampling of parameters using a Latin Hypercube Sampling. Results include a minimum of 100 000 replicates. This model was not fitted but the range of parameter values were defined according to literature	Extensive simulations and ensembles of simulated infection trajectories generated for ranges of combinations consistent with observed infection behaviors.	Fitted the model to each of the 63 individual charts using a steepest-descent algorithm to determine the parameter set that minimized the sum of squared deviations. Starting values based on the literature and their previous work.	Two steps: a deterministic fit to the first wave of parasitemia, and a second stochastic step for parasitemia patterns following the initial wave. Based on these steps ‘best choices’ of in-host parameters are selected, by defining min/max ensemble envelop’ by minimizing its

								distance from the ensemble mean curve
Outcome tested for the fitting	distribution of durations of infection from malariatherapy as well as the minimum, median, and maximum of the 9 summary statistics			max parasitemia, number of days with fever, number of days with parasitemia higher than 10 per microliter, number of days with parasitemia higher than 10000 per microliter		first parasite density peak, lower secondary peaks, and even lower peaks after 100 days, the possibility of reinfection with homologous strains, the interval between peaks, and the distribution of measured durations.	asexual parasite density and gametocyte parasite density over time for each patient chart	asexual parasite density over time for each patient chart
Fitted parameters	$q, k_c, k_m, P_v^*, \kappa_c, \kappa_v, \kappa_m$ $C, \sigma, \delta_v, \delta_m, \beta$	$\kappa_c, \sigma, P_c^*, P_m^*$	$\sigma, g, P_v^*, \kappa_m, f(t)$	$c, SF, k, m_0, \alpha, \Psi$	All parameter values are explored within ranges	Ranges of several parameters ($X_{50,innate}, C_{innate}, C_{antibody}, C_{minormod}, C_{merozoite}, K_{MSP}, Y_{memory}, K_{antigen}$) are investigated	$a-z, zy, p, s, c, k, q, b, r$	A, B, p, f_a, f_b, m

References

1. Molineaux L, Diebner HH, Eichner M, Collins WE, Jeffery GM, Dietz K. *Plasmodium falciparum* parasitaemia described by a new mathematical model. *Parasitology*. 2001 Apr;122(4):379–91.
2. Johnston GL, Smith DL, Fidock DA. Malaria's Missing Number: Calculating the Human Component of R0 by a Within-Host Mechanistic Model of Plasmodium falciparum Infection and Transmission. Antia R, editor. *PLoS Comput Biol*. 2013 Apr 18;9(4):e1003025.
3. Sama W, Dietz K, Smith T. Distribution of survival times of deliberate Plasmodium falciparum infections in tertiary syphilis patients. *Trans R Soc Trop Med Hyg*. 2006 Sep;100(9):811–6.
4. Challenger JD, Bruxvoort K, Ghani AC, Okell LC. Assessing the impact of imperfect adherence to artemether-lumefantrine on malaria treatment outcomes using within-host modelling. *Nat Commun*. 2017 Dec;8(1):1373.
5. Gatton ML, Cheng Q. Investigating antigenic variation and other parasite-host interactions in Plasmodium falciparum infections in naive hosts. *Parasitology*. 2004 Apr;128(4):367–76.
6. Paget-Mcnicol S, Gatton M, Hastings I, Saul A. The Plasmodium falciparum var gene switching rate, switching mechanism and patterns of parasite recrudescence described by mathematical modelling. *Parasitology*. 2002 Mar;124(3):225–35.
7. Gatton ML, Peters JM, Fowler EV, Cheng Q. Switching rates of Plasmodium falciparum var genes: faster than we thought? *Trends Parasitol*. 2003 May;19(5):202–8.
8. Peters J, Fowler E, Gatton M, Chen N, Saul A, Cheng Q. High diversity and rapid changeover of expressed var genes during the acute phase of Plasmodium falciparum infections in human volunteers. *Proc Natl Acad Sci*. 2002 Aug 6;99(16):10689–94.
9. Eckhoff P. P. falciparum Infection Durations and Infectiousness Are Shaped by Antigenic Variation and Innate and Adaptive Host Immunity in a Mathematical Model. Snounou G, editor. *PLoS ONE*. 2012 Sep 19;7(9):e44950.
10. Malaria infection and immune model — Malaria Model documentation [Internet]. [cited 2020 Nov 2]. Available from: <https://docs.idmod.org/projects/emod-malaria/en/latest/malaria-model-infection-immunity.html>
11. Selvaraj P, Wenger EA, Gerardin J. Seasonality and heterogeneity of malaria transmission determine success of interventions in high-endemic settings: a modeling study. *BMC Infect Dis*. 2018 Aug 22;18(1):413.
12. Gerardin J, Ouédraogo AL, McCarthy KA, Eckhoff PA, Wenger EA. Characterization of the infectious reservoir of malaria with an agent-based

- model calibrated to age-stratified parasite densities and infectiousness. *Malar J*. 2015 Jun 3;14(1):231.
13. McCarthy KA, Wenger EA, Huynh GH, Eckhoff PA. Calibration of an intrahost malaria model and parameter ensemble evaluation of a pre-erythrocytic vaccine. *Malar J*. 2015 Jan 7;14(1):6.
 14. Childs LM, Buckee CO. Dissecting the determinants of malaria chronicity: why within-host models struggle to reproduce infection dynamics. *J R Soc Interface*. 2015 Mar;12(104):20141379.
 15. Gurarie D, Karl S, Zimmerman PA, King CH, St. Pierre TG, Davis TME. Mathematical Modeling of Malaria Infection with Innate and Adaptive Immunity in Individuals and Agent-Based Communities. Paul RE, editor. *PLoS ONE*. 2012 Mar 28;7(3):e34040.
 16. McKenzie FE, Bossert WH. An integrated model of *Plasmodium falciparum* dynamics. *J Theor Biol*. 2005 Feb;232(3):411–26.